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JHDMs (JmjC-domain-containing histone demethylases) are the largest class 
of demethylase enzymes, contain a Jumonji C (JmjC) domain and catalyze lysine 
demethylation of histones through an oxidative reaction that requires Fe(II) ion and 
α-ketoglutarate (2OG) as cofactors. The misregulation of these enzymes, in 
particular JMJD2 subfamily, has being significantly implicated in cancer initiation 
and progression. Potent and specific inhibitors of these enzymes have not been 
identified yet, most of them inhibiting many other Fe(II)/2OG dependent 
oxygenases or being affected by undesirable characteristics.  
Here, we describe the discovery by high throughput screening (HTS) of a 
bunch of novel hit compounds active against KDM4s and the subsequent hit 
validation stage to select the most interesting ones for further derivatization. The 
use of a multiple combined approach of different in vitro techniques led us to select 
the hit EML586 as starting point for the development of novel optimized 
derivatives.  
The substitution of quinoxaline ring with more aliphatic portions gave 
derivatives such as EML678 and EML684, which demonstrate a better activity 
against hKDM4A compared to the starting hit compound. Furthermore, they 
induced a marked reduction in methylation of lysines H3K9 and H3K27 in a cell-











Almost all nucleated cells of human body contains the complete genome 
sequence; epigenetic changes, among other mechanisms, enable the differentiation 
of pluripotent stem cells into the somatic cells that make up different organs and 
tissues in the body1. 
Etymologically, the term epigenetics is derived from the Greek επί (epì) 
γεννετικός (genetikòs), which literally means “above or beyond genetics”. The term 
was first coined in 1942 by Conrad Waddington, defining it as “causal interactions 
between genes and their products which bring the phenotype into being”2. Over the 
years, the concept of epigenetics has been repeatedly expanded and revised. To 
date, the most comprehensive definition is that formulated by Bird in 2007, 
according to which epigenetic events are "the structural adaptation of chromosomal 
regions so as to register, signal or perpetuate altered activity states"3. This definition 
does not include the concept of "inheritance”, peculiar characteristic of many 
epigenetic alterations but not of all of them. 
 
1.2. The genome organization 
 DNA within eukaryotic cells is condensed in chromatin. The nucleosome is 
the core unit of chromatin and is composed of an octamer of four different histones 
(H3, H4, H2A, and H2B), around which DNA is wound with a length of 




Figure 1.1. The gene organization. Pictures modified from Lodish, H et al. 
Molecular cell biology 1999. 
 
For many years, the main function of the histone packaging of DNA was 
considered to be to compact the double helix into a repressive structure; now we 
understand that the nucleosome is an active participant in both repression and 
activation of eukaryotic genes, and that the proper coordination of gene expression 
involves the dynamic action of hundreds of chromatin protein factors5.  
 
1.3. The epigenetic enzymes 
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DNA and histone proteins can undergo various post-synthetic modifications. 
These modifications, along with histone variants and nucleosome remodelers, can 
strongly influence chromatin structure and transcriptional regulation without 
changing the underlying DNA sequence, in a process called “epigenetic 
regulation”. Epigenetic regulation can be separated into three inter-related layers: 
nucleosome positioning, histone modifications, and DNA methylation6. It is widely 
accepted that these mechanism are intricately interrelated, working together to 
determine the status of gene expression and to decide cell fate7. 
Ever since Allfrey’s pioneering studies in the early 1960s, we have known 
that histones are post-translationally modified. There are a large number of different 
histone post-translational modifications (PTMs), including methylation, 
acetylation, phosphorylation and ubiquitination8. Distinct histone modifications can 
generate synergistic or antagonistic interaction affinities for chromatin-associated 
proteins, which in turn dictate dynamic transitions between transcriptionally active 
or silent chromatin states. The combinatorial nature of histone modifications thus 
suggests a “histone code” that considerably extends the information potential of the 
genetic code9. 
Histone modifications are catalyzed by a large variety of histone-modifying 
enzymes, which are able to read, add or remove covalent modifications to histone 
proteins4. They are generally divided into three categories: enzymes that add 
chemical marks to histone substrates, the so-called writers such as histone 
acetyltransferases (HATs) and histone methyltransferases (HTMs); enzymes that 
remove such chemical covalent modification from histone substrates-namely, 
erasers such as histone deacetylases (HDACs) and histone lysine demethylases 
(KDMs); and proteins that recognize and react to specific modified histone residues 





Figure 1.2. Classification of epigenetic enzyme. Pictures modified from 
Copeland, R. A. et al. Nat Rev Drug Discovery 2009. 
 
1.4. Histone methylation 
Histone methylation is an important epigenetic modification in chromatin. 
Lysine and arginine residues can be methylated. The number of methyl groups that 
can be incorporated at a specific residue is different and seems to be determinant to 
transcription. Thus, the ε-amino group of lysines can be mono-, di-, or 
trimethylated, while the guanidino-ε-amino groups of arginines can accommodate 




Figure 1.3. Lysine (A) and arginine (B) methylation states.  
 
Histone methylation is regulated by a complex network that involves a large 
number of site-specific methylases (HMTs), demethylases (HDMs) and methyl 
recognition proteins12, which play an important role in many biological processes, 
including cell-cycle regulation, DNA damage- and stress response, embryonic 
development and cellular differentiation4, 13.  
Arginine/lysine methylation is catalysed by S-adenosyl-methionine-
dependent methyltransferases (HMTs), that can be grouped into two divergent 
families: histone lysine methyltransferases (HKMTs) catalyzing the methylation of 
lysine residues and protein arginine methyltransferases (PRMTs) catalyzing the 
methylation of arginine residues11.  
The introduction of a methyl group, despite not altering the amino acid 
charge, induces alterations in the chromatin architecture. In contrast with 
acetylation/deacetylation of the histone tails, where in general acetylation reduces 
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DNA–nucleosomal interactions to facilitate transcription, methylation on either 
lysine or arginine residues of the histone tails can be associated with either 
condensation or relaxation of the chromatin structure. Since several sites for 
methylation are present on each tail, different combinations are possible14-15.  
Furthermore, it should also be remembered that methylation of lysine and 
arginine residues is not only limited to histones. Several methyltransferases have 
been identified to methylate many non-histone proteins including RelA, p53, 
estrogen receptors and TAF10, regulating moreover distinct functions of NF-κB16-
18. 
 
1.5. Histone demethylase proteins (HDMs) 
HDMs are enzymes that, as the name suggests, remove methyl groups from 
lysine and arginine residues in both histone and non-histone proteins. 
Although for many years N-methylation was thought to be a stable, 
irreversible modification, the reversal of lysine methylation is now well established. 
In 2004, the first mammalian histone lysine demethylase (KMD) was reported to 
be a flavin-containing amino oxidase (AO) that specifically demethylated mono or 
dimethylated lysine 4 at histone H3 (H3K4me1 and H3K4me2) and has been named 
LSD1 (lysine-specific demethylase 1)/KDM1A19. 
Since then this area of research has grown exponentially with the 
identification of a second flavin-dependent H3K4me1/2 demethylase called LSD2/ 
KDM1B20 and a larger and more versatile family of KDMs, structurally different 
from LSD1, working through a Fe(II)/2-oxoglurate (2OG) mechanism for 
catalysis21-22.  
In contrast to lysine methylation, the extent to which arginine methylation is 
dynamic is much less clear. The peptidyl-arginine deiminases (PADs) catalyse the 
hydrolysis of the guanidino arginine side chain to the urea group of citrulline23-24. 
In this reaction, demethylimination is not a ‘true’ demethylation reaction: it 
removes but does not reverse N-methylation because produces neutral citrulline, 
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which has considerably different chemical properties compared to unmethylated 
arginine.  
Recently, some KDMs have been reported to catalyze methylarginine 
demethylation25-27; however, their biological role in these processes is still 
controversial and it merits further investigation. 
 
1.6. Histone lysine demethylases (KDMs) 
Removal of the N-methyl tag on lysine residues of histone proteins is carried 
out by two different classes of oxidative enzymes. LSDs (Lysine specific 
demethylases) are a class of enzymes that directly reverse histone H3K4 or H3K9 
modifications by an oxidative demethylation reaction in which flavin adenine 
dinucleotide (FAD) is a cofactor19. JHDMs (JmjC-domain-containing histone 
demethylases) are the second class of oxidative demethylase enzymes. These 
enzymes catalyse demethylation thought a reaction that requires iron Fe(II) and 
2OG as cofactors22. 
 
1.6.1. Lysine specific demethylases (LSDs) 
Mammals contain so far only two flavoenzyme demethylases: LSD1 and 
LSD2 known also as KDM1A and KDM1B19-20.  
In the early 60s, it was observed for the first time a demethylase activity that 
could demethylate modified lysine by an amine oxidase (AO) reaction in tissue 
extracts. It was proposed a mechanism in which FAD was a cofactor and 
formaldehyde and unmethylated lysine were reaction products28. The reaction was 
catalyze by an enzyme called LSD1, identified several years later as a component 
of a histone deacetylase (HDAC) protein complexes29-30. Based on the presence of 
LSD1 in chromatin-modifying complexes and its predicted FAD-dependent AO 
function, it was proposed as the long-sought-after FAD-dependent histone 
demethylase enzyme19.  
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LSD1 shows a robust demethylase activity with specificity towards histone 
H3 methylated on lysine 4 (H3K4), but it can demethylate also non-histone targets, 
such as K370me1 and K370me2 on p5331, Lys1096 on DNA methyltransferase 1 
(DNMT1)32 and Lys185 on E2F133. 
The other LSD family member, LSD2 (KDM1B) has so far only been shown 
to demethylate H3K4me1 and H3K4me220, 34. Furthermore, characterization of the 
LSD2 complex reveals that LSD2 forms active complexes with euchromatic histone 
methyltransferases G9a and NSD3 as well as cellular factors involved in 
transcription elongation. These data provide a possible molecular mechanism 
linking LSD2 to transcriptional regulation after initiation35.  
These enzymes are related to the well-characterized monoamine oxidases 
(MAOs). Structurally, both LSDs consist of an N-terminal SWIRM domain and an 
amine oxidase-like (AOL) domain containing 2 sites to bind the methylated 
substrate and the FAD cofactor, respectively (Figure 1.4).  
 
Figure 1.4. Crystallographic structure of LSD1: amine oxidase-like (AOL) 
domain with FAD (magenta) and SWIRM domain (green). PDB: 2HKO. 
 
Only in LSD1, between these 2 sites in the AOL domain, there are 2 
antiparallel α-helices project away as a unique feature forming the Tower domain, 
crucial for the interaction of LSD1 with other proteins and for the ability to 
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demethylate nucleosomal substrates10, 36-38. Otherwise, LSD2 has an amino-
terminal zinc finger domain of unknown function39.  
The catalytic activity resides in the AOL domain, which uses an oxidation 
mechanism that is dependent on the cofactor FAD to catalyse the removal of methyl 
groups from histone lysine residues. The catalytic mechanism relies on a lone 
electron pair on the lysine ε‑nitrogen atom, and for this reason the LSD enzymes 
can demethylate mono- and demethylated lysines but not trimethylated lysines 
(Figure 1.5)40. 
 
Figure 1.5. Mechanism of action of LSDs.  
 
Given the structural similarities with MAOs, amongst the first reported 
KDM1 inhibitors there were structures as phenelzine and tranylcypromine 
(PCPA)41. Subsequent studies supported by crystallographic analyses, have utilized 
tranylcypromine as a scaffold for the development of a good number of analogues, 
modified on both the aromatic ring and amino groups. These inhibitors display both 
improved potency, especially against KDM1A, and, in some cases, also selectivity 




Figure 1.6. Some inhibitors of LSD1. 
 
Interestingly, the LSD1 inhibitor ORY-1001 is currently in a phase I/IIA 
clinical trial in patients with relapsed or refractory acute leukemia43.  
 
1.6.2. Jumonji-C domain-containing histone demethylase (JHDMs) 
JHDMs are the second and largest class of demethylase enzymes. They 
contain a Jumonji C (JmjC) catalytic domain and catalyse lysine demethylation of 
histones through an oxidative reaction that requires iron Fe(II) and 2-oxoglurate as 
cofactors21-22, 44.  
The name of this family is correlated with the high conserved JmjC-domain 
that was first identified in the protein JARID245. Jumonji means cruciform in 
Japanese: the gene was so named because mutant mice on jmj locus develop an 
abnormal cross-like neural tube45. 
 This enzyme class is part of a much larger superfamily, the 2OG oxygenases, 
whose members (about 80 genes in the human genome) catalyse a diverse range of 
oxidation reactions46, e.g. enzymes involved in the hypoxic response pathway47-49. 
Among the 30 JmjC domain-containing proteins identified so far within the human 
genome, about 20 have been found to possess histone demethylase activity. Six 
different subfamilies (JMJD1s, JMJD2s, JARID1s, UTX/Y-JMJD3, PHFs, and 
FBXLs) of JHDMs have been described, which have different histone sequence and 




Figure 1.7. Phylogenetic tree of JHDMs. Pictures modified from Johansson, C. et 
al. Epigenomics 2014. 
 
The JmjC domain is characterized by a double-stranded β-helical (DSBH) 
fold, also called the “jelly-roll” fold, composed of eight β-strands which are 
arranged antiparallel to each other to form a β-sandwich structure52. The active site 
is located at one end of the DSBH fold, employing a two-histidine-one-carboxylate 
“facial triad” to coordinate the catalytic Fe(II) center, while 2OG interacts with two 
residues that are also conserved among the members of the JHDM family40, 49. 
Most JHMDs also contain additional secondary structure elements, including 
at least one helix to the C-terminal side of the DSBH, that surround the domain and 
define the different subfamilies53-54. 
The catalytic mechanism for JHDMs is provided in Figure 1.8. The two 
cofactors, Fe(II) and 2‑oxoglutarate, react with dioxygen to form a highly active 
oxoferryl (Fe(IV)=O) intermediate that hydroxylates the methyl groups of the 
methylated lysine substrate53, 55. The resulting lysyl hemiaminal is unstable and is 
hydrolyzed to release the methyl group from nitrogen in the form of formaldehyde. 
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This mechanism allows for the demethylation of lysines in all three methylation 
states (mono-, di- and trimethylated lysines)56-57.   
 
Figure 1.8. Catalytic mechanism of JHDMs. 
 
Although this reaction is common to JHDM enzymes, crystallographic 
analyses have shown that variations in the size of the active site region are in part 
responsible for the methylation state selectivity53. Similarly, also the presence of 
non-catalytic domains, including the PHD, Tudor, CXXC, FBOX, ARID, LRR, as 
well as JmjN domains, regulates demethylase selectivity to particular residues58-59.  
Furthermore, mounting evidence suggests that some JmjC demethylases are 
also able to demethylate non-histone substrates60.  
 
1.7. The Jumonji-C domain-containing protein 2 family (JMJD2) 
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The subfamily of JMJD2s (called KDM4s in an alternative, more recent, 
nomenclature) is one of the largest among the JHDMs61. Six Jmjd2 genes are 
present in the human genome, coding for as many different isoforms classified 
according to an alphabetical order from A to F62.  
Jmjd2E and -F, whose gene products are very similar to KDM4D, are 
considered pseudogenes and, only recently, Jmjd2E expression has been observed, 
suggesting its role as a functional gene. However, the catalytic domain of human 
KDM4E is highly active and shows similar substrate specificities as KDM4D63. 
KDM4 subfamily enzymes are highly conserved; KDM4A–C orthologues 
exist in all genome-sequenced vertebrates with earlier animals containing only a 
single KDM4 enzyme. Contrarily, KDM4D orthologues only exist in eutherians 
placental mammals where they are conserved, including proposed substrate 
sequence-determining residues63.  
The KDM4A-C proteins share more than 50% sequence identity and contain 
JmjN, two plant homeodomains (PHD) and two Tudor domains in addition to the 
JmjC domain. KDM4D-F, in contrast, contain only the JmjN and JmjC domains. 
As for the other JHDMs, the JmjC domain bears catalytic function in KDM4s, while 
the JmjN domain interacts extensively with JmjC and provides structural integrity 
(Figure 1.9)57, 61. Phylogenic analysis shows that KDM4A and KDM4C are more 
similar to one another than KDM4B and KDM4D. They all contain the conserved 




Figure 1.9. Active site of KDM4A with 2OG (magenta). JmjC domain (red) and 
JmjN domain (blue) are visible. PDB: 2Q8E.  
 
Crystallographic data of KDM4A revealed that the active site of this 
subfamily enzymes is larger and more open than other JHDM demethylases due to 
the presence of an adjacent aliphatic subpocket64. Moreover, there is a secondary 
Cys3-His Zn(II) binding site close to the N-methyl lysine-residue binding site. 
Bioinformatic analyses indicated that none of the other JHDM subfamilies (or 
indeed other 2OG oxygenases) identified to date have a comparable Zn-binding site 
close to their catalytic domain (although some do have structurally diverse Zn(II) 
binding sites in other domains likely involved in binding to chromatin)65. This site 
can be may be involved in substrate recognition. 
Biochemical studies indicate that KDM4A-C catalyze the removal of H3K9 
and H3K36 di- and trimethyl marks, while KDM4D can only demethylate 
H3K9me3/me2. KDM4E meanwhile, catalyzes the removal of two methyl groups 
from H3K9me3 and H3K56me366. 
Beyond the catalytic core of KDM4A-C, the C-terminal PHD and Tudor 
domains bear important histone reader functions. Structural and biochemical 
studies have demonstrated that the Tudor domains of KDM4A can recognize and 
bind two unrelated histone marks, H3K4me3/me2 and H4K20me3/me2, by means 
of distinct binding mechanisms67-69. Furthermore, the PHD domains in other histone 
regulatory proteins have been demonstrated to bind unmodified or modified histone 
residues on one or more histone tails, offering flexibility in directing epigenetic 
modifications70. However, to date, no functional studies of the KDM4s PHD 
domains have been reported, highlighting the need to clarify the molecular function 
of these domains. 
 
1.7.1. The physiological role of KDM4s 
Kdm4 genes are expressed in various human tissues; KDM4A-C are broadly 
expressed in the spleen, ovary and colon, while KDM4D is predominantly 
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expressed in the testes71. KDM4 proteins can be found in multiprotein complexes 
known to participate in transcriptional regulation and epigenetic remodeling. 
KDM4A is the most abundant and the most studied isoform. Through 
H3K9me3 demethylation, it promotes an open chromatin state, contributing to the 
transcription activation of promoter regions. Contrarily, the outcome of KDM4A-
mediated demethylation of H3K36 is less clear72. KDM4A is also implicated in 
replication timing and genomic stability73.  
KDM4A abundance is cell cycle-dependent, and this protein antagonizes the 
function of heterochromatin protein 1 gamma (HP1g)73. Additionally, KDM4A is 
involved in the DNA damage response together with KDM4B through their Tudor 
domains that bind to the methylated residues of H4. After DNA damage, 
KDM4A/B is ubiquitinated by RNF8 and RNF168 and degraded by the proteasome, 
allowing the binding of 53BP1 to H4K20me2. Furthermore, KDM4A 
overexpression abrogates 53BP1 recruitment to DNA damage sites, suggesting a 
possible role of KDM4A in the DNA damage response74.  
KDM4A has also been found to play a key role in the regulation of p53 
through its function, in complex with a F-box protein, as a novel E3 ubiquitin ligase 
targeting methylated p53 for degradation at the late senescent stage75. 
More recently, it was proposed that KDM4A possesses the potential to act as 
an oxygen sensor in the context of chromatin modifications, with possible 
implications for epigenetic regulation in hypoxic disease states76.  
 
1.7.2. The pathological role of KDM4s 
Perturbations in heterochromatin and histone methylation are common 
characteristics of tumor cells77-78 Global changes in histone methylation patterns 
can be found in several tumor types, such as breast, prostate, lung, and ovarian 
cancer79-81. In particular, there is an abundance of data linking aberrations in H3K9 
methylation to cancer82-83.   
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The KDM4 proteins are capable of modifying the epigenetic landscape, and 
several tumor types have been identified that overexpress one of these 
demethylases. For example, KDM4B levels are increased in colorectal cancer84 and 
medulloblastoma85 and functions as an oncogene in breast cancer86-87. In particular, 
KDM4B mRNA levels are higher in ERα-positive breast cancer where there is a 
cooperative interaction between KDM4B and ERα to allow the transcription of 
several oncogenes and anti-apoptotic genes87.  
KDM4A overexpression plays a key role in prostate cancer progression. 
KDM4A and KDM4B are overexpressed in prostate cancer and KDM4A and 
KDM4D both bind the androgen receptor (AR), stimulating AR-induced 
transcription that is the driving force behind the development and progression of 
pathology88-89. 
Also KDM4C is overexpressed in several tumor types including breast 
cancer90, esophageal squamous cell carcinoma91, and Hodgkin lymphoma92.  
The association of KDM4 overexpression with malignancy is a reflection of 
their role in promoting cellular proliferation. For each of KDM4A–D, forced 
overexpression is associated with increased cellular proliferation and anchorage-
independent growth89. Moreover, knockdown of the overexpressed KDM4 proteins 
reduces these oncogenic characteristics87, 93-94.  
Aberrant KDM4s activity is also associated with cardiac hypertrophy95, 
cellular response to hypoxia76 and DNA damage response94. 
 
1.8. KDM4s: a relevant therapeutic target 
Given the role of KDM4s in various diseases, especially cancer, the 
development of specific KDM4 inhibitors is the focus of several research groups. 
In the following section will be presented a summary of the main inhibitor class 
described so far in the literature.  
 
1.8.1. The 2OG derivatives  
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First promising results in the research for KDM4 inhibitors were provided, as 
often happens, from the efforts to target the cofactors essential for the activity of 
this class of enzymes. This strategy aims to obtain cofactor analogues that could 
interact with the catalytic domain of KDM4s, where 2OG is normally bound, but 
unable to take part in the reaction of demethylation. 
N-oxalylglycine (NOG) is a closely related analogue of 2OG wherein the C-
3 methylene group is replaced with an NH group. It was one of the first disclosed 
JmjC demethylase inhibitors and represents the simplest compound within this class 
(Figure 1.10). NOG mimics the initial coordination of the 2OG, occupying the same 
position and forming the same set of hydrogen bonds, but it does not initiate the 
hydroxylation process96. Although first described as a prolyl hydroxylase (PHD) 
inhibitor, NOG is a broadspectrum inhibitor of many 2OG oxygenases and was then 
mostly used as a biochemical tool compound for in vitro testing97. 
 
Figure 1.10. Structure of NOG.  
 
The identification of suberanilohydroxamic acid (SAHA), a histone 
deacetylase (HDAC) inhibitor, as a KDM4E inhibitor, together with the knowledge 
that hydroxamic acids are good iron chelators, led to the design of inhibitors where 
the 2-oxoacid group of 2OG is replaced with a hydroxamic acid moiety. The 
resulting compounds containing the hydroxamic acid scaffold show good 
selectivity for the KDM4 family over the related 2OG oxygenases, improved by the 
addiction of a carbon linker bearing a protonated tertiary amine likely function 
(Figure 1.11)98-99. However, the presence of a carboxylic acid function makes these 




Figure 1.11. Hydroxamic acid derivatives.  
 
Pyridine dicarboxylates are more rigid 2OG analogues than NOG and the 
acyclic hydroxamic acids, although they share the same mechanism of action. The 
pyridine-2,4-dicarboxylic acid (2,4-PDCA) is the broadest-spectrum 2OG 
oxygenase inhibitor, and is an inhibitor of most JHDMs. Its JHDM activity has also 
been confirmed in cell through the use of ester prodrugs100. Subsequent 
derivatizations have led to 3-substitued and bipyridine compounds; although there 
has been improvement in potency, these inhibitors remain unselective towards the 
2OG-dependent oxygenases (Figure 1.12)101-102.  
 
Figure 1.12. Pyridine dicarboxylates derivatives. 
 
1.8.2. 8-Hydroxyquinoline-based KDM4s inhibitors  
Interestingly, variously substituted 8-hydroxyquinoline derivatives have been 
identified as KDM4 inhibitors through a high-throughput screen campaign (Figure 
1.13). Among them, the 5-carboxy-8-hydroxyquinoline (IOX1) was the most active 
inhibitor displayed an IC50 of 0.2 μM in vitro and cellular activity (HeLa cells), 
despite its poor cellular permeability. The IOX1 inhibitory mechanism was linked 
to its capacity to chelate Fe(II) in the enzyme active site in a bidentate manner via 
its quinoline nitrogen and phenol oxygen atoms. For the same reason, IOX1 is 
active against many other 2OG-dependent enzymes (KDM3A, KDM6A, KDM2A, 




Figure 1.13. IOX1 and other 8-hydroxyquinoline derivatives.  
 
Recently, research for novel JMJD2A inhibitors by using IOX1 as active 
moiety led to a novel series of 2-substituted derivatives with a potent JHDMs 
inhibitory activity and selectivity over PHD2 (Figure 1.14). Despite the better 
physico-chemical properties compared to IOX1, these compounds are still limited 
by poor cellular permeability104.  
 
Figure 1.14. Novel 2-substituted 5-carboxy-8-hydroxyquinoline derivatives. 
 
1.8.3. Other Fe-chelating KDM4s inhibitor scaffolds 
Triazolopyridines have been reported as a potent scaffold for JHDMs 
inhibition105. In these compounds the alternative triazole metal binding motif was 
incorporated to the known 2,2’-bipyridine-4-carboxylate scaffold. Crystallographic 
studies demonstrated that they bind KDM4A active site via metal chelation. A good 
number of analogues were synthesized leading to selective KDM2 and KDM5 





Figure 1.15. Triazolopyridines development.  
 
Towards a rational approach, a tetrazoylhydrazide scaffold compound has 
been identified to be active against KDM4A, with 4-fold and 41-fold selectivity 
over KDM5A and KDM6B, respectively (Figure 1.16)106. However, this scaffold 
provided limited opportunity for expansion into unexplored space having few 
points of appendage variation; the terminal hydrazide substitution was not tolerated 
and the alkyl chain extension lead to less than 2-fold potent compounds106. 
 
Figure 1.16. 2-(1H-tetrazol-5-yl)acetohydrazide as the most active compound of 
this class 
 
1.8.4. KDM4s inhibitors of natural origin 
In the last few years, a lot of natural products as flavonoids and catechols 
have been demonstrated to inhibit a number of 2OG oxygenases, including the 
KDM4s107. In one of these studies, a catechol series, caffeic acid derivatives, was 
found to inhibit KDM4C and KDM6A but not PHF8 (Figure 1.17)108. These 
compounds didn’t compete directly with 2OG and it is possible that multiple factors 




Figure 1.17. Catechols with inhibitory activity against KDM4s.  
 
Recently, the natural product Tripartin, a dichlorinated indanone isolated 
from Streptomyces sp. associated with a larva of a dung beetle, has been reported 
as a KDM4 inhibitor (Figure 1.18). Activity in a cell-based assay against KDM4 
has been reported, but we have no evidence about the mechanism of action and 
selectivity109. 
 
Figure 1.18. Tripartin, a KDM4 Inhibitor from a bacterium associated with a 
dung beetle larva. 
 
1.8.5. Noncatalytic domain targeting KDM4s inhibitors 
Among the KDM4s inhibitors described in the literature, there are also 
compounds, such as Disulfiram and Ebselen, approved or investigated for the 
treatment of other pathologies (Figure 1.19). 
 
Figure 1.19. Disulfiram (left) and Ebselen (right). 
 
Disulfiram is an aldehyde dehydrogenase inhibitor that was used to treat 
alcoholism by producing an extremely aversive reaction when taken in the presence 
of alcohol, and thus considered a deterrent110. 
Ebselen mimics glutathione peroxidase activity and catalyzes several 
essential reactions for the protection of cellular components from oxidative and  free 
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radical damage. It is currently under clinical trials for the prevention and treatment 
of various disorders such as cardiovascular diseases, arthritis, stroke, 
atherosclerosis, and cancer111.  
The inhibitory effect of these compounds was conferred by their ability to fit 
into the Cys3-His Zn(II) binding site, close to the active site, displacing the Zn2+ 
ion. This causes a conformational change in the protein so that binding of N-
methylated lysine at the close active site is altered. 
This allosteric inhibition occurred only in KDM4s because, as mentioned in 
Paragraph 1.7, none of the other JHDM subfamilies have a comparable Zn-binding 
site close to their catalytic domain65.  
 
 
1.8.6. Substrate competitive inhibitors 
Recently, highly conjugated arylalkenes, including curcumin derivatives, 
have been identified as competitive inhibitors with respect to histone H3K9me3 
against KDM4A and KDM4B (Figure 1.20). These compounds shown induced 
apoptosis in cancer cells and negatively regulated androgen receptor (AR)-
responsive genes112-113.  
 
Figure 1.20. Arylalkenes derivatives as KDM4 inhibitors. 
 
 However, curcumins are known to be promiscuous inhibitors highlighted as 
pan-assay interference (PAINS) compounds114.  
 
1.8.7. Other inhibitors of KDM4s 
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In the last years, also cyclic peptide sequences were selected as novel 
inhibitor scaffolds for the KDM4s115. Interestingly, these peptides, with a good in 
vitro potency but no activity in cells, bind KDM4s in “allosteric sites”115. 
Recently, also metal-containing inhibitors of KDM4s were reported, as for 
some iridium(III) complexes. However, discrepancy between the data obtained and 
the unclear mechanism of action suggest that these molecules are able to interact 
with other proteins115.  
 
1.9. Specific demethylation assays used in lead discovery 
The identification of JHDMs modulators over the last decade has been 
supported by the development of several screening methods in order to evaluate 
compounds potency, selectivity, binding and mechanism of action.  
Biochemical assays are the most common ones, as they give a quantitative 
measure of the ability of the compound to influence target activity. In most cases, 
activity was related to the level of reaction products (methylated peptides, 
formaldehyde) or reagents (2OG), that can be measured in a direct or indirect 
manner. 
On the other hand, biophysical methods are capable of measuring the 
equilibrium binding constants between pairs of molecules crucial for molecular 
recognition processes, encompassing protein–protein, protein–small molecule, and 
protein–nucleic acid interactions, and several can be used to measure the kinetic or 
thermodynamic components controlling these biological processes. For a full 
characterization of a binding process, determinations of stoichiometry, binding 
mode, and any conformational changes associated with such interactions are also 
required. The suite of biophysical methods that are now available represents a 
powerful toolbox of techniques which can effectively deliver this full 
characterization116. 
In the following paragraphs, it will be presented a summary of the main 
JHMDs-specific screening technique described so far in the literature, highlighting 




1.9.1. Indirect demethylation methods 
Indirect methods are well-established in many areas of drug discovery and 
are often amenable to high-throughput screening according to their advantageous 
characteristics (high versatility, fast results, low costs). 
The FDH-coupled assay is a miniaturized fluorescence-based assay used for 
the identification of new JHDMs inhibitors. In this assay, formaldehyde released 
from demethylation of the histone peptide substrate was detected by converting it 
to formic acid using a second enzyme: formaldehyde dehydrogenase (FDH). The 
oxidation of formaldehyde is coupled to the reduction of nicotinamide adenine 
dinucleotide (NAD+) to NADH, which is monitored by fluorescence spectroscopy 
(Figure 1.21)97, 107, 117.  
 
Figure 1.21. Principle of FDH-coupled inhibition assay. 
 
However, FDH-coupled assay can be problematic due to its vulnerability to 
measurement errors and lack of reliability. The screening results could be easily 
affected by interferences arising from factors including compound auto-
fluorescence, noisy/partial concentration responses, false positives acting on the 
coupled-enzyme component of the assay, and promiscuous inhibitors or potent 
metal chelators103. To this end, the combined use of an orthogonal assay greatly 
increases the reliability of data obtained. 
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Other assays capable of detecting and quantifying formaldehyde, generating 
fluorescent adducts, have become available over the past few years. However, they 
share the same limitations discussed above.  
The AlphaLISA homogeneous proximity immunoassay is another commonly 
used indirect assay. In this assay, the photosensitizer phthalocyanine is dissolved 
on a polystyrene donor bead. Excitation with 680 nm light induces phthalocyanine 
to convert ambient oxygen to singlet oxygen molecules with a 4 μs half-life. These 
molecules can diffuse 200 nm freely through solution. If a polystyrene acceptor 
bead is within the lifetime of the singlet oxygen species, the singlet oxygen will 
react with an Europium chelate. The Europium (Eu) chelate is directly excited by 
the 340 nm light resulting from the conversion of thioxene to a di-ketone derivative 
following its reaction with singlet oxygen. The excited Europium chelate generates 
an intense light detectable within a much narrower wavelength bandwidth centred 
around 615 nm. In the KDM4-specific catalytic assay, a streptavidin-coated donor 
and anti-H3K9me2-coated acceptor bead pair were used to detect the demethylation 
of biotinylated H3K9me3 peptide (Figure 1.22)118. 
 
Figure 1.22. Principle of the AlphaLISA homogeneous proximity immunoassay 
technology. 
 
However, also AlphaLISA may be sensitive to different types of 
interferences. For example, antioxidants or other quenchers of reactive oxygen 
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species like metal ions can strongly affect the emitted signal, as well as biotin-like 
compounds can compete for the interaction of biotinylated substrate with Donor 
beads. Moreover, colored compounds absorbing in the 500-600 nm wavelength 
range can artificially decrease the signal and therefore may be detected as false 
positives119.   
 
1.9.2. Direct demethylation methods 
Direct methods are more specific and, generally, reliable alternatives to 
quantify JHDMs activity. These techniques have less problems of false positives 
and negatives, but are generally more expensive in terms of time and money. For 
this reason, direct methods are used most frequently in advanced-stages of drug 
discovery. 
Mass spectrometry methods are widely used to determinate histone 
modifications, in both enzymatic and cell-based assays. LC-MS and MALDI-TOF 
represent an alternative approach that can address the complexity of histone PTMs 
in single experimental set and overcome some of the limitations of antibody-based 
methods (such as specificity, availability, limited dynamic range and by problems 
in detecting multiple modifications). However, they require more complex sample 
preparation methods, longer times, and more material compared to other methods, 
resulting in more difficulties for high-throughput.  
Nondenaturing mass spectrometry has been used to assess binding of 
potential inhibitors to JMJD2s, but also to explore the extend of binding pocket 
though a disulfide exchange based dynamic combinatorial-mass spectrometry 
(DCMS) screen. In this method, a compound that binds to the active site (the 
support ligand) which contains a thiol is allowed to react (either on the enzyme in 
the active site, or in solution) with a set of thiols to form a mixture of disulfides. 
Nondenaturing ESI-MS is then used to analyze which disulfides bind preferentially 
to the enzyme120. However, In these ESI-MS analyses, it is important to appreciate 
that different types of noncovalent interaction survive the transition from solution 








Several KDM4s inhibitors have been identified over the last few years, as 
described in Paragraph 1.8. In most cases, these molecules are recognized within 
the active site by residues that interact with 2OG and are, for this reason, capable 
to compete with it. Despite their clear inhibitory activity in various biochemical 
assays, the use of these compounds in cell-based assays in order to clarify the role 
of KDM4s in pathological processes is limited by their undesirable characteristics. 
In particular, many inhibitors described in literature have poor cell permeability, 
which limits their applicability as chemical probes and their potential therapeutic 
development. Moreover, these structures are often unselective; to be useful as 
probes, KMD4s inhibitors should not inhibit at least some of the other Fe(II)/2OG 
dependent oxygenases, e.g., those involved in the hypoxic response pathway, 
including the factor-inhibiting HIF (FIH) and the human HIF prolyl hydroxylase 
domain 2 (PHD2).  
In this regard, the aim of my PhD project was to develop new selective and 
cytopermeable small-molecule modulators of KDM4 subfamily enzymes in order 
to obtain a useful chemical probe that could help us to elucidate the role of 
demethylation in cell-based assays. 
 
2.1. High-Throughput Screening for the identification of new hits 
In 2012, a commercially available library of compounds preselected for 
epigenetic target was screened using an indirect fluorescence assay for human 
KDM4 (hKDM4) in the laboratory of Professor Axel Ihmof at Ludwig-
Maximilians-Universität (Munich, Germany). From this high-throughput screening 
(HTS) campaign it has been possible to identify a pool of eight hits (Figure 2.1), all 
characterized by a good inhibitory potency, with an IC50 in the low micromolar 




Figure 2.1. Initial hits identified by high-throughput screening. 
 
Table 2.1. IC50 values of hits identified by HTS. 
hits IC50 (μM) 
 














2.2. Fragment-based ligand discovery 
Identified hits have low molecular weight and very simple structure, meeting 
fully or partially to the “rule of three”, useful to classify a molecule like 
“fragment”121-122. For this reasons, we decided to describe these compounds as 
pseudo-fragments, using gathered information as starting point for development of 
a fragment-based ligand discovery (FBLD) campaign. 
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In FBLD, identification of active fragments is generally supported by 
information about their binding mode. With this information, it is possible to guide 
the development of larger and more complex structures that target additional 
interactions in the active site of the protein. This strategy appears to be particularly 
appropriate in the case of biological targets for which very little is known about 
selectivity, although there is the possibility of generating inactive or less active 
compounds compared to starting hits. Furthermore, a diverse range of scaffolds 
should provide a higher chance for discovery of small-molecule biological 
functional modulators123. 
For this reason, in collaboration with Professor Rino Ragno of Università 
degli Studi di Roma “La Sapienza”, an efficient in silico model was generated on 
the basis of the crystallographic data available in the literature (PDB IDs: 2GP5, 
2OQ7, 2OS2, 2OT7, 2OX0, 2PXJ, 2Q8C, 2Q8D, 2Q8E, 2VD7, 2WWJ, 2YBK, 
2YBP, 2YBS, 3NJY, 3PDQ, 3RVH, 3U4S, 4AI9, 4GD4). A cross-docking study 
was performed and the software PLANTS(CHEMPLP) was selected based on two 
parameters: docking accuracy (DA) and average value of root-mean-square 
deviation (RMSD). Despite the computational studies are not the first choice in this 
kind of approach, the availability of solved crystallographic structures along with 
the possibility to use multiple templates to build models have improved the quality 
of our in silico model. The pseudo-fragments have been docked in this model, 
highlighting the hypothetical key interactions that they create within the active site. 
Different docking poses were generated and the ones with the lowest free energy 
were selected for further studies. 
Based on computational data, we have combined crucial non-overlapping 
moieties and designed a small library of chimera compounds (Figure 2.2), with the 
aim to establish the maximum amount of skeletal diversity and structural 
complexity, but also to build more complex structures, key factors toward 




Figure 2.2. Overlap of hits F2 (plum) and F7 (deep pink) within the catalytic 
domain. 
 
The designed chimera compounds have been docked with the same 
computational model, in order to predict and classify binding affinity of molecules 
(Table 2.2). Structures with the lowest free energy have been synthesized and 
screened against hKDM4 (Chapters 3 and 4).  







F2 and F6 -164,602 
 




F2 and F7 -147,161 
 
F2 and F3 -133,463 
 
F1 and F3 -111,426 
 
Unfortunately, as will be described in Chapter 4, biochemical evaluation of 
chimera molecules certified their complete absence of inhibitory activity. These 
results could depend from excessive structural rigidity of derivatives than starting 
pseudo-fragments, as well as from some mistakes in initially formulated 
hypotheses.   
 
2.3. Hit validation process and further derivatizations 
To better understand negative results, chimera molecules together with the 
starting hits, was further investigated by Imhof and collaborators through a more 
reliable, direct screening platform, based on mass spectrometry (MS), as triage tool 
to confirm inhibition and identify true positives. It was found a good inhibitory 
potency only for three among the eight initial hits, whereas other two were endowed 
with modest activity and the remaining three compounds resulted completely 




Figure 2.3. Real actives from HTS campaign. 
 
Nevertheless, this result is not so surprising. The indirect assay initially used, 
despite advantageous characteristics in terms of speed, cost and versatility, also has 
disadvantages; artifacts from the coupled enzyme reaction can easily lead to false 
positives and negatives, which require a thorough counter-screen to eliminate. 
Furthermore, experience had shown that not all the “actives” discovered through 
HTS are of equal value in terms of progression in the Hit-to-Lead (HtL) phase.  
Therefore, we decided to take a step back restarting from real actives 
identified during HTS campaign, focusing this time on the validation of active 
compounds as well as on the evaluation of hit classes on the basis of both target-
independent and target-dependent criteria, following generic rules described in 
literature124-125. The goal was to identify the most promising lead candidates in order 
to increase possibilities to obtain potent and selective KDM4 inhibitors.  
Therefore, hits were re-synthesized, structurally confirmed and evaluated for 
purity and stability by NMR, MS and HPLC experiments. Compounds with reactive 
functionality or other undesirable chemotypes were removed. Also biophysical and 
biochemical assays were performed to evaluate cell permeability, synthetic 
accessibility, activity, selectivity and preliminary structure-activity relationships 
(SARs). 
This process is significantly expensive in terms of time and money, but it is 




As will be widely described in Chapter 4, compound EML586 (F6) has been 
selected for further derivatization over the other two. Starting from its 3-hydroxy-
2,3-dihydroquinazolin-4(1H)-one scaffold, we designed a small library of novel 
analogues (Figure 2.4) as will be discussed in Chapter 4.  
 
 













3.1. Synthesis of thiophene-2-sulfonamide derivatives 
The first derivatives that have been synthesized were designed by the 
combination of fragment F2 and F7 (Chapter 2). These chimeras are characterized 
by a thiophene core. 
The synthesis of the thiophene-2-sulfonamide derivatives 96a-b has been 
developed starting from the ethyl thiophene-2-carboxylate 98, which was treated 
with chlorosulfonic acid and then with in chloroform to yield a mixture of 
regioisomers 99a-b. After removing the excess acid through liquid-liquid 
extraction, the mixture was used without further purification. Finally, the reaction 
with tert-butylamine in dry tetrahydrofuran gave corresponding sulfonamides 
100a-b (Scheme 3.1). 
 
Scheme 3.1. Reagents and conditions: (a) chlorosulfuric acid, CH2Cl2, room 
temperature, overnight; (b) tert-butylamine, triethylamine, dry THF, room 




 The regioisomeric mixture of sulfonamides 100a-b was treated with lithium 
hydroxide to hydrolyse the ester function and the corresponding acids (101a-b) 
were separated by preparative high performance liquid chromatography (HPLC). 
Coupling reaction with the 1-(pyridin-2-ylmethyl)piperazine (102) in the presence 
of  N,N'-dicyclohexylcarbodiimide (DCC) and 4-(dimethylamino)pyridine 





Scheme 3.2. Reagents and conditions: (a) lithium hydroxide, THF/H2O, room 
temperature, 2 h (95%); (b) DCC, DMAP, dry CH2Cl2, room temperature, 
overnight (75%). 
 
Tert-butyl group was removed with trifluoroacetic acid and the corresponfing 
sulfonamides sulfonimides 95a-b were acylated with pivaloyl chloride in the 
presence of triethylamine to yield the desired N-(thiophenylsulfonyl)pivalamides 
96a and 96b (Scheme 3.3). 
 
Scheme 3.3. Reagents and conditions: (a) trifluoroacetic acid, CH2Cl2, room 
temperature, overnight (95%); (b) pivaloyl chloride, triethylamine, dry CH2Cl2, 
room temperature, overnight (70%). 
 
3.2. Synthesis of quinoxaline derivative 
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The second chimera compound was designed from apposition of the 
fragments F2 and F6 and it was characterized by a quinoxaline core. It was obtained 
through a convergent synthesis in which the key step was the condensation of the 
2-amino-N-hydroxybenzamide 33 with the 2-formylquinoxaline 112 in methanol at 
room temperature (Scheme 3.4)126. Product was readily purified by column 
chromatography and recovered in good yields. 
 
Scheme 3.4. Reagents and conditions: (a) MeOH, room temperature, 2 h (68%). 
 
The following paragraphs will describe the synthesis optimization of the key 
intermediates. 
 
3.2.1. Construction of the quinoxaline core 
Initially, we tried to build quinoxaline ring following classical procedures that 
involve the condensation of an aromatic ortho-diamine with an α-dicarbonyl 
derivatives127-128. This kind of reactions are generally very accessible having simple 
reaction conditions, good yield and using readily available starting materials and 
reagents. 
According to this, o-diamine derivative 113 was prepared from 2-nitroaniline 
(110) in a three-step sequence. Treatment with mono-ethyl oxalyl chloride to give 
111 was followed by chlorosulfonation to give intermediate 112 in good yield. 
Subsequent nitro reduction with zinc powder in acetic acid easily gave compound 
113 (Scheme 3.5). All the compounds were readily purified through liquid-liquid 




Scheme 3.5. Reagents and conditions: (a) mono-ethyl oxalyl chloride, Et2O, 
room temperature, 3 h (99%); (b) chlorosulfuric acid, neat, 80 °C, 3 h then tert-
butylamine, triethylamine, dry THF, room temperature, 0.5 h (78%); (c) zinc 
powder, acetic acid, room temperature, 0.5 h (95%). 
 
Ortho-diamine derivative 113 was then treated with methylglyoxal (114) in 
acetonitrile at room temperature to give the 7-substituted-2-methylquinoxaline 108. 
As expected, the coupling reaction gave a mixture of regioisomers, affording also 
the 2,6-disubstituted derivative 116 (Scheme 3.6) in a 50:50 ratio. Contrary to what 
happened with the thiophene derivatives, in this case it was not possible to separate 
the molecules exploiting HPLC, due to their very similar chromatographic profiles. 
 
Scheme 3.6. Reagents and conditions: (a) ACN, room temperature, 1 h (90%a).  
 a108:116 = 45:55 ratio as determined by NMR analysis. 
 
Trying to exploit the differential nucleophilicity of amino function on the 
ortho-diamine derivative 113, we developed a different strategy in which it was 
treated with the commercially available α-hydroxy acetone 115, at low temperature. 
Also in these conditions, the outcome of reaction was the mixture of regioisomers, 




Scheme 3.7. Reagents and conditions: (a) ACN, 0 °C, 1 h (80%a). a108:116 = 
70:30 ration as determined by NMR analysis. 
 
Subsequently, we tried to use a pair of orthogonal protecting groups, to 
selectively access to single amine, but also this approach ultimately failed.  
Acylation of 2-nitroaniline derivative 112 with acetic anhydride gave compound 
117 which was sequentially reduced using zinc powder and acetic acid, at room 
temperature, to afford amine 118. The second amino function was then protected 
with di-tert-butyl dicarbonate to give compound 119 in low yield (Scheme 3.8).  
 
Scheme 3.8. Reagents and conditions: (a) acetic anhydride, acid acetic, reflux, 
2.5 h (90%); (b) zinc powder, acetic acid, room temperature, 0.5 h (77%); (c) di-
tert-butyl dicarbonate, iodine, MeOH, room temperature, overnight (25%). 
 
Unexpectedly, isolation of compound 120, obtained by selective removal of 
the acetyl group, was not possible due to a side intramolecular reaction. In fact, the 
Boc group, stable under the conditions of removal of the acetyl, reacts with the 
amine function released and hydroxybenzoimidazole 121 was obtained as a main 
product (Scheme 3.9).  
 
Scheme 3.9. Reagents and conditions: (a) lithium hydroxide, THF/H2O, room 




Therefore, to obtain 7-substituted-2-methylquinoxaline we look for different 
synthesis methods. Finally, we succeded in obtaining the desired compound using 
an intra-molecular copper-catalysed hydroamination.  Starting from the procedure 
of Knapp et al.129, the reported procedure was modified improving yield, decreasing 
reaction time and enhancing atom economy lowering copper-catalyst required.  In 
the following paragraph details have been reported. 
Sulfonamide derivative 104 was obtained by chlorosulfonation of 
commercially available 2-chloronitrobenzene (103) according to the procedure 
already described for compound 112. After chloride substitution with 
propargylamine (105), nitro group was reduced with iron sulphate in ammonia 
aqueous solution yielded 3-amino-N-(tert-butyl)-4-(prop-2-yn-1-
ylamino)benzenesulfonamide (107) in good yield (Scheme 3.10). 
 
Scheme 3.10. Reagents and conditions: (a) chlorosulfuric acid, neat, 120 °C, 1 h 
then tert-butylamine, triethylamine, THF dry, room temperature, 0.5 h (85%); (b) 
propargylamine, triethylamine, EtOH, 120 °C (mw), 1.5 h (65%); (c) iron(II) 
sulfate heptahydrate, ammonium hydroxide solution, H2O, EtOH, reflux, 1 h 
(90%). 
 
As reported by Knapp, the primary amino group of 107 intramolecularly 
reacts with the triple bond in a hydroamination reaction catalyzed by a cuprous salt 
used in stoichiometric amount (Scheme 3.11). 
 




Despite large related literature, there are few cases of hydroamination 
employing a cuprous catalyst. Moreover, examples of this intramolecular reaction 
to build heterocycles are still less. For these reasons, together with the need to 
improve initially low yield (9%), we made a methodology work to optimize the 
reaction, which results are reported in Table 3.1.  
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Table 3.1. Optimization of hydroamination reaction. aNumber of microwave heating cycles are indicated. bIsolated yield after 




solvent timea (h) Yieldb (%) 
starting 
materialc 
Tetrakis(acetonitrile)copper(I) tetrafluoroborate (1.00 eq) 90 dry toluene 20 9 - 
Tetrakis(acetonitrile)copper(I) tetrafluoroborate (1.00 eq) 90 (mw) dry toluene 4x0.5 23 - 
Tetrakis(acetonitrile)copper(I) tetrafluoroborate (1.00 eq) 90 (mw) dry acetonitrile 0.5 33 - 
Tetrakis(acetonitrile)copper(I) tetrafluoroborate (1.00 eq) 90 dry acetonitrile 5 31 - 
Tetrakis(acetonitrile)copper(I) tetrafluoroborate (1.00 eq) 90 (mw) dry ethanol 0.5 29 - 
Tetrakis(acetonitrile)copper(I) tetrafluoroborate (0.10 eq) 90 (mw) dry acetonitrile 4x0.5 49 - 
Tetrakis(acetonitrile)copper(I) tetrafluoroborate (0.10 eq) 90 (mw) dry acetonitrile 2x0.5 13 77 
Tetrakis(acetonitrile)copper(I) tetrafluoroborate (0.10 eq) 90 dry acetonitrile 11 67 8 
Tetrakis(acetonitrile)copper(I) tetrafluoroborate (0.10 eq) 90 (mw) dry ethanol 5x0.5 39 18 
Tetrakis(acetonitrile)copper(I) tetrafluoroborate (0.10 eq) 90 (mw) dry acetonitrile 3x0.5 33 9 
Copper(I) iodide (0.10 eq) 90 (mw) dry acetonitrile 3x0.5 40 - 
Copper(I) iodide (0.10 eq) 90 (mw) dry ethanol 8x0.5 43 9 
Copper(I) iodide (0.10 eq) 90 °C dry acetonitrile 9 54 2 
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Copper(II) tetrafluoroborate hydrate (0.10 eq) 90 °C dry acetonitrile 4x0.5 38 9 
Copper(I) iodide (0.10 eq) 130 °C dry acetonitrile 0.25 41 3 
Copper(I) iodide (0.10 eq) 130 °C dry acetonitrile 0.125 29 24 
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With the proper 7-substituted-2-methylquinoxaline 108 in hand, the desired 
key synthon 109 was easily obtained by oxidation of methyl substituent using 
selenium dioxide in reflux toluene (Scheme 3.12).  
 
Scheme 3.12. Reagents and conditions: (a) selenium dioxide, dioxane/H2O, 
reflux, 1 h (81%). 
 
3.2.2. Synthesis of 2-amino-N-hydroxybenzamide (33) 
2-amino-N-hydroxybenzamide (33) was the second building block required 
for the synthesis of the chimera compound 97. Starting from commercially 
available isatoic anhydride (122), which was coupled with O-protected 
hydroxylamine, hydroxamic acid 33 was obtained by deprotection of the protected 
intermediate 124 (Scheme 3.13). 
 
Scheme 3.13. Reagent and conditions: (a) ACN, reflux, 3 h (90-95%); (b) 
various reagents and conditions.  
 
The protection of hydroxy group was necessary because direct reaction 
between isatoic anhydride (122) and hydroxylamine (123c) leads to the formation 




Scheme 3.14. Reagent and conditions: (a) ACN, reflux, 3 h (25%). 
 
Two different protecting groups, the benzyl (Bn) and the tetrahydro-2H-
pyran-2-yl (THP) groups, were considered. As will be described in detail below, 
both protecting groups can be easily added, but only the THP can be readily 
removed. 
 
3.2.2.1. Synthesis and deprotection of 2-amino-N-(benzyloxy)benzamide (127a) 
Scheme 3.15 describes the synthetic strategies used to obtain 2-amino-N-
(benzyloxy)benzamide protected on the oxygen with the benzyl group (124a) and 
its subsequent deprotection.  
 
Scheme 3.15. Reagents and conditions: (a) K2CO3, DMF, room temperature, 5 h 
(96%); (b) NH2NH2·H2O, Et2O, room temperature, 2 h (99%); (c) ACN, reflux, 
3h (90%); (d) various reagents and conditions. 
 
Alkylation of N-hydroxy phthalimide 126 with benzyl bromide (127) in DMF 
straightforwardly gave compounds 129a, which can be easily precipitated by 
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adding water to the reaction mixture and recovered in good yield and purity. 
Without any purification step, it was treated with hydrazine monohydrate at room 
temperature in diethyl ether to afford compound 123a. After removing the main 
impurities by liquid-liquid extraction, pure compound was recovered by 
evaporation of solvents under reduced pressure.  
The coupling reaction between isatoic anhydride (122) and O-benzyl 
hydroxylamine (123a) gave the compound 124a, readily purified by column 
chromatography. Unfortunately, it was not possible to find an efficient strategy to 
remove the benzyl group. Different procedures were carried out; always product 33 
has been obtained in moderate yield after long purification processes due to the 
presence of the side product 130.  
Below, the most relevant deprotection procedures will be briefly described 
(Scheme 3.16). 
 
Scheme 3.16. Reagents and conditions: (a) H2, Pd/C 10%, EtOH, room 
temperature, overnight (45%); (b) 1,4-cyclohexadiene, Pd/C 10%, MeOH, 120 °C 
(mw), 4 min, (53%). 
 
2-amino-N-(benzyloxy)benzamide (124a) has been deprotected under 
hydrogen atmosphere, using palladium on active carbon (10%) as catalyst. The 
reaction gave compound 33 together with the side product 130 in moderate yield. 
A similar result was also obtained under microwave-assisted catalytic transfer 
hydrogenation conditions, using 1,4-cyclohexadiene as mild hydrogen donor. 
For above mentioned reasons, it was considered appropriate to change the 




3.2.2.2. Synthesis and deprotection of 2-amino-N-((tetrahydro-2H-pyran-2-
yl)oxy)benzamide (127b) 
The use of THP protecting group follows a similar synthetic route compared 
to benzyl group just described (Scheme 3.17).  
 
Scheme 3.17. Reagents and conditions: (a) para-toluensulfonic acid, 
CH2Cl2/dioxane, room temperature, 3.5 h (99%); (b) (b) NH2NH2·H2O, Et2O, 
room temperature, 2 h (99%); (c) ACN, reflux, 3h (90%); (d) Amberlyst® 15 
hydrogen form, MeOH, 50 °C, 3h (95%). 
 
According to literature procedures130, O-THP hydroxylamine 124b can be 
conveniently synthesized treating commercially available N-hydroxy phthalimide 
(126) with 3,4-dihydro-2H-pyran (128) in the presence of a catalytic amount of 
para-toluensulfonic acid. As described before for benzyl derivative, compound 
129b was treated with hydrazine monohydrate at room temperature in diethyl ether 
to afford the corresponding O-protected hydroxylamine 123b.  
The coupling reaction between isatoic anhydride (122) and O-THP 




Unlike the benzyl, the removal of THP group was easily obtained under acidic 
conditions, using the ion exchange resin Amberlyst® 15 hydrogen form. The 
reaction gave 2-amino-N-hydroxybenzamide (33) in high yield (95%) after 
recrystallization.  
 
3.3. Synthesis of triazole derivatives  
As will be described in Chapter 4, real actives from HTS have been re-
synthesized in order to evaluate characteristics like chemical accessibility and 
stability and, in some cases, also to evaluate preliminary structure-activity 
relationships.  
The hit compound F1 (80a) and its derivatives have been synthesized 
according to general procedure described in literature131 (Scheme 3.18).  
 
Scheme 3.18. Reagents and conditions: (a) semicarbazide hydrochloride, sodium 
acetate, ACN, room temperature, 1 h (95-99%); (b) sodium hydroxide solution 2 
N, reflux, 6 h (95-99%). 
 
A variety of commercially available aryl isothiocyanates (81a-e) were treated 
with semicarbazide in the presence of sodium acetate in acetonitrile at room 
temperature to give thiobiureas 82a-e which were heated at 100 °C in the presence 
of 2 M NaOH aqueous solution for 6 h to afford the desired 3-hydroxy-5-thiol 
derivatives 78a-e. Both the steps are characterized by excellent yields.  





Scheme 3.19. Reagents and conditions: (a) dry THF, room temperature, 1 h 
(55%); (b) hydrazine hydrate, EtOAc, room temperature, 4 h (90%); (c) 
formamidine acetate salt, acetic acid, DMF, 80 °C, 8 h (60%). 
 
Para-methoxyaniline (83) was converted to phenylcarbamate 85 by reacting 
with phenyl chloroformate (84) at room temperature. Compound 85 was then 
treated with hydrazine hydrate to give semicarbazide 86, which was subsequently 
reacted with formamidine acetate in the presence of DMF at 80 °C to give the 
triazolone 79.  
 
3.4. Synthesis of N-(5-ethyl-1-(2-morpholinoethyl)-3-oxoindolin-2-
yl)acetamide 
The synthesis of hit F8 (80) has been developed starting from the 5-ethyl 
isatin (91), which was synthesized from para-ethylaniline (87) and chloral hydrate 
(88) exploiting the classical Sandmeyer isatin synthesis133. Isatin 89 was 
subsequently N-alkylated with 2-morpholinoethan-1-ol, previously activated with 
methanesulfonyl chloride (90), to give compound 91 in good yield (Scheme 3.20).  
 
Scheme 3.20. Reagents and conditions: (a) hydroxylamine hydrochloride, 
sodium sulfate, HCl acqueos solution 5%, H2O, 95 °C, 2 h, then H2SO4 conc., 80 




5-ethyl-1-(2-morpholinoethyl)indoline-2,3-dione (91) was then treated with 
ammonia solution in methanol to yield the corresponding imide 92, which was 
quickly treated with sodium cyanoborohydride at -78 °C in tetrahydrofuran. After 
a proper reduction time, the very unstable amino intermediate was directly acylated 
with acetic anhydride without any purification step. Anhydride was added at -78 °C 
and the mixture was allowed to slowly warm to ambient temperature while stirring. 
This two-step reaction yielded a mixture of isomers as described in Scheme 3.21. 
 
Scheme 3.21. Reagents and conditions; (a) saturated ammonia solution in 
MeOH, formic acid (catalytic), room temperature, 3 h (80%); (b) sodium 
cyanoborohydride, dry THF, -78 °C, 6 h, then acetic anhydride, room 
temperature, overnight (20%). 
 
Finally, separation of isomers by preparative HPLC provided compound 80 
in low yield.  
 
3.5. Synthesis of 3-hydroxy-2,3-dihydroquinazolin-4(1H)-one derivatives 
(1-30) 
The key step for the synthesis of 3-hydroxy-2-(quinoxalin-2-yl)-2,3-
dihydroquinazolin-4(1H)-one derivatives 1-30 was the condensation of the 2-
amino-N-hydroxybenzamide 33 with the proper aldehyde (34-63) in methanol at 
room temperature (Scheme 3.22)126. The reaction times varied according to 
aldehyde solubility from 1 to 24 hours. All the compounds were readily purified by 








Figure 3.1. Aldehydes used for the synthesis of compounds 1-30 
 
Table 3.2. All 3-hydroxy-2,3-dihydroquinazolin-4(1H)-one derivatives 
synthesized.  aIsolated yield.  
entry compound aldehyde R1 R2 R3 R4 
yielda 
(%) 
1 EML586 34 - - - - 84 
2 EML621 35 - - - - 87 
3 EML622 36 - - - - 85 
4 EML623 37 - - - - 90 
5 EML624 38 H H H H 77 
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6 EML647 39 H H Cl H 81 
7 EML648 40 H H NO2 H 83 
8 EML649 41 H H OCH3 H 79 
9 EML658 42 H H F H 80 
10 EML678 43 H H CF3 H 85 
11 EML679 44 H Cl Cl H 81 
12 EML680 45 Cl H Cl H 82 
13 EML681 46 F H Cl H 85 
14 EML682 47 F H H Cl 80 
15 EML645 48 - - - - 74 
16 EML646 49 - - - - 77 
17 EML651 50 - - - - 65 
18 EML657 51 - - - - 82 
19 EML650 52 - - - - 88 
20 EML659 54 H H H H 68 
21 EML655 55 H H Cl H 71 
22 EML652 56 H H NO2 H 73 
23 EML653 57 H H OCH3 H 70 
24 EML654 53 H H OH H 67 
25 EML656 58 H H CH3 H 71 
26 EML683 59 H H CF3 H 75 
27 EML684 60 H Cl Cl H 73 
28 EML685 61 Cl H Cl H 77 
64 
  
29 EML686 62 F H Cl H 74 
30 EML687 63 F H H Cl 73 
 
3.5.1. Synthesis of quinazolin-4(3H)-one derivatives 
Aromatic analogues 31-32 were obtained from oxidation with selenium 
dioxide of compounds 1 and 2 respectively, in toluene (Scheme 3.23) 
 
Scheme 3.23. Reagents and conditions: (a) selenium dioxide, toluene, 
reflux, 4 h (80%).  
 
Compounds are readily purified by column chromatography and collected in 
good yield.  
 
3.5.2. Synthesis of non-commercially available aldehydes 
While aldehydes 34-37 and 51-63 are commercially available, aldehydes 38-





Scheme 3.24. Reagents and conditions: (a) NaBH4, MeOH, room temperature, 0.5 h (95-99%); (b) mesyl chloride, triethylamine, dry 
CH2Cl2, 0° C, 3.5 h (95-99%); (c) potassium carbonate, acetone, reflux, 1 h (75-85%).
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Commercially available aldehydes 54-64 have been readily reduced using 
sodium borohydride in methanol to give the corresponding benzyl alcohols 67a-
76a with quantitative yield. The alcohol group was then activated with 
methanesulfonyl chloride (derivatives 67b-76b) and reacted with proper 
hydroxybenzaldehyde (55, 65-66) to give products 38-49. Reactions were carried 
out in acetone with potassium carbonate. After chromatographic purification, 
aldehydes derivatives were collected in good yields (Table 3.3).   




R1 R2 R3 R4 
yielda 
(%) 
38 54 H H H H 77 
39 55 H H Cl H 85 
40 56 H H NO2 H 79 
41 57 H H OCH3 H 84 
42 64 H H F H 81 
43 57 H H CF3 H 88 
44 58 H Cl Cl H 77 
45 59 Cl H Cl H 75 
46 60 F H Cl H 84 
47 61 F H H Cl 75 
48 - - - - - 79 





Finally, reaction between para-hydroxybenzaldehyde 55 and tosyl chloride 
(77) in CH2Cl2 in presence of triethylamine gave aldehyde 50 in high yield (Scheme 
3.25).  
 
Scheme 3.25. Reagents and conditions: (a) triethylamine, dry CH2Cl2, room 












4.1. Biochemical evaluation of chimera molecules 
As described in Chapter 2, the identification of eight hit compounds by HTS 
guided us toward a FBLD approach, supported by molecular docking studies.  
A small pool of chimera molecules has been designed combining non-
overlapping binding portions of different fragments and then have been docked with 
the same computational model, in order to predict and classify their binding affinity. 
According to computational prioritization, the most promising ones have been 
synthesized, as described in Chapter 3 (Figure 4.1).  
 




Chimera molecules, together with some reaction intermediates, have been 
screened against hKDM4A by the FDH-coupled assay, in collaboration with 
Professor Axel Imhof at Ludwig-Maximilians-Universität (Munich, Germany). 
Unfortunately, no inhibitory activity was found for any of the prepared 
compounds. These results could depend from excessive structural rigidity of 
derivatives than starting pseudo-fragments, as well as from some mistakes in 
initially formulated hypotheses. 
 
4.1.1. Orthogonal screening platform  
In order to better understand negative results and increase the reliability of 
data obtained, a new and more reliable screening platform has been developed in 
the lab of Professor Imhof, to orthogonal confirm compounds activity by mass 
spectrometry. To this aim, the activity of the hKDM4A was calculated, in the 
presence and without inhibitors, by LC-MS and MALDI-TOF through the direct 
measurement of the level of histone methylation. MALDI-TOF was also used to 
quantify the activity of KDM4A of Drosophila (dKDM4A).  
Exploiting these assays, chimera molecules have been tested again, showing 
no activity in all the three different conditions. At the same time, we also evaluated 
the activity of initial hit compounds by the new screening platform. Results have 
confirmed a good inhibitory potency only for three of them (Figure 4.2), certifying 





Figure 4.2. Real active identified by orthogonal screening 
 
Unfortunately, our combined molecules are composed, partially or totally, by 
the inactive hits identified as false positives. This may explain the total lack of 
activity of them. 
 
4.2. Hit validation process 
The identification of only three real positives, among the eight hit compounds 
selected by HTS, persuaded us to take a step back and focus our attention on the 
prioritization of the hits in order to identify the most promising lead candidates and 
increase possibilities to obtain potent and selective KDM4 inhibitors.  
This process is significantly expensive in terms of time and money, but it 
generally allows to avoid high attrition rate during the lead optimization phase.  
To this aim, we evaluated hits on the basis of both target-independent and 
dependent criteria, following the generic rules described in the literature (Table 
4.1)124-125. 
Table 4.1. Generic Criteria for Hit Validation  
1. structural identity confirmed 
2. tractable synthetic route established 
3. purity and stability established 
4. structure free of reactive/undesirable chemotypes 
5. structure reasonably drug-like 
6. activity confirmed on solids 
7. not a promiscuous inhibitor 
8. logical structure-activity relationship (SAR) 
 
At first, actives were re-synthesized. As described in Chapter 3, compounds 
EML615 and EML586 are synthetically accessible in high yields. On the contrary, 
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the synthesis of EML627 was affected by the formation of a mixture of two 
regioisomers, that lowered yield and increased purification time.  
All compounds were structurally confirmed and evaluated for purity by NMR 
and HPLC experiments. 
 
4.2.1. Chemical stability assay 
The stability of compounds has been evaluated after incubation in phosphate-
buffered saline (PBS) aqueous solution. Small molecule compounds can be unstable 
in aqueous solutions with respect to hydrolysis and this was considered a major 
issue because can significantly affect their application as molecular probes.  
Therefore, compounds EML586, EML615 and EML627 were incubated 
with PBS solution, at room temperature. The presence of degradation products in 
the samples was evaluated by HPLC analysis after 5, 15, 30, 60 minutes and 24 h 
(Figure 4.3).  
 
Figure 4.3. HPLC chromatograms obtained for compound EML627 injected 
immediately after the dissolution in PBS, after 5, 15, 30, 60 minutes and 24 h. 
Spectra were recorded at 220 nm. 
 
Experimental results indicated that the compounds EML586 and EML615 
were stable under the conditions routinely used in biological assays (see Chapter 












6). On the contrary, the high susceptibility of EML627 to degradation in aqueous 
buffer appeared as a strong limitation, considering its incompatibility with all 
cellular assays conditions. Therefore, in addition of its poor synthetic accessibility, 
we decided to discard its chemotype for further derivatization.  
 
4.2.2. Parallel artificial membrane permeability assay  
Subsequently, we evaluated the cell permeability of EML586 and EML615.  
To this aim, the well-validated parallel artificial membrane permeability assay 
(PAMPA) technique was employed134-135. The highly permeable drug propranolol 
and the poorly permeable drug furosemide were used as references (Table 4.2).  
In PAMPA, a donor compartment, containing a buffer solution of selected 
compound, was separated by a filter plate coated with a liquid artificial membrane 
from an acceptor compartment, containing initial fresh buffer solution. Permeability 
was determined by measuring the delivery rate of chemical permeated into the 
acceptor compartment from the donor one during an incubation of 24 h at room 
temperature. A solution of dodecane was used as artificial membrane, providing 
significant correlations with gastrointestinal absorption in humans.  
Table 4.2. Apparent permeability values of EML586 and EML615 with respect 
to standards propranolol and furosemide. 
Compound Papp (cm/s) 
Propranolol 4.1 x 10-6 
EML586 1.5 x 10-6 
EML615 0.2 x 10-6 




The compound EML586 showed an apparent permeability value (Papp) of 1.5 
× 10−6 cm/s, similar to that of propranolol (Papp = 4.1 × 10
−6 cm/s), and very different 
from furosemide (Papp = 0.09 × 10
−6 cm/s).  
On the other side, EML615 showed a poor apparent permeability value (Papp 
= 0.2 × 10−6 cm/s), probably due its more hydrophilic structure. 
 
4.2.3. Secondary screening  
Once both chemical stability and cell permeability were established, 
EML586 and EML615 have been tested against a panel of non-metal catalysed in-
house epigenetic enzymes (PRMT1, PRMT3) and, again, on hKDM4A, using a 
different biochemical assay: the AlphaLISA homogeneous proximity 
immunoassay. 
As described in Chapter 1, this type of assay measured enzyme activity by 
detecting the methylation grade of a biotinylated histone H3 peptide using 
streptavidin-coated donor beads and AlphaLISA acceptor beads conjugated to an 
antibody directed against the modified substrate. 
This additional independent biochemical assay was useful to confirm on solid 
activity against hKDM4A, as well as to elucidate a perspective on potential 
promiscuity of the inhibitors against other epigenetic targets.  
Compounds have been tested at the fixed dose of 100 μM (5% DMSO) and 































































































Figure 4.4. AlphaLISA assay performed with the hKDM4, PRMT1 and PRMT3. 
Enzyme activity percentage determined at 100 μM (5% DMSO) with respect to 
DMSO. The results reported are the means ± SD determined for at least two 
separate experiments. 
 
Both the compounds have been shown no activity against PRMT enzyme, 
while they were able to completely inhibit hKDM4 activity at this concentration.   
 
4.3. Preliminary SARs 
Hit validation last stage was to identify consistent SARs of actives to 
corroborate structure-based activity and develop a pharmacophore hypothesis. To 
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meet this, we designed and synthesized a small pool derivatives containing 
EML586 and EML615 scaffolds. 
 
4.3.1. Structure-activity relationships of triazole derivatives  
The active EML615 was characterized by a very simple structure. For this 
reason, we decided to apply a molecular complication strategy to generate more 
complex derivatives, in order to explore the space availability into the active pocket. 
To meet this aim, we introduced an aromatic ring in place of the cyclopropane on 
the nitrogen N1, directly connected to the triazole moiety or separated by an alkyl 
chain (1 or 2 carbon atoms). Subsequently, we decided to explore the importance 
of the sulfhydryl group, in order to verify its possible role in metal-interactions. All 
designed derivatives are summarized in Figure 4.5. 
 
Figure 4.5. Derivatives of active EML615. 
 
The compounds were synthesized (Chapter 3) and tested using the 
AlphaLISA homogeneous proximity immunoassay against hKDM4A at 50 μM (5% 
DMSO) fixed concentrations (data shown in Table 4.3). 
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Table 4.3. Effects of EML615 derivatives on the activity of hKDM4A. Enzyme 
activity percentage determined at fixed dose of 50 μM (5% DMSO) with respect 
to DMSO. The results reported are the means ± SD determined for at least two 
separate experiments. 
Compound % residual activity hKDM4A  
EML615 20.8 ± 2.3 
EML587 43.8 ± 5.8 
EML588 47.9 ± 4.0 
EML617 no inhibition 
EML618 no inhibition 
EML619 no inhibition 
 
All derivatives synthesized were less active than EML615. Removal of the 
sulfhydryl group led to inactive compound EML619. On the other hand, 
introduction of an aromatic ring resulted in moderately active compounds 
(EML587 and EML588), but only when it was directly bound to the triazole ring. 
In fact, the insertion of an alkyl chain gave the inactive derivatives EML617 and 
EML618, suggesting a limited space availability into the active pocket.  
These results led us to discard also triazole moiety for further derivatization 
because this scaffold provided limited opportunity for expansion into unexplored 
space having few points of appendage variation. 
  
4.3.2. Structure-activity relationships of 3-hydroxy-2,3-dihydroquinazolin-
4(1H)-one derivatives 
The development of EML586 derivatives has initially involved the 
replacement of one or both nitrogen atoms on quinoxaline to obtain the 
corresponding quinoline and naphthalene derivatives, in order to elucidate their role 
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in metal-interactions. Furthermore, hydroxamic function in 3-hydroxy-2,3-
dihydroquinazolin-4(1H)-one ring has been removed to obtain 4-hydroxy-
quinazoline derivatives through dehydration (Figure 4.6). 
 
Figure 4.6. Derivatives of active EML586. 
 
As for the triazole derivatives, compounds have been tested using the 
AlphaLISA homogeneous proximity immunoassay against hKDM4A at 50 μM (5% 
DMSO) fixed concentrations (data shown in Table 4.4). 
Table 4.4. Effects of compounds on the activity of hKDM4A. Enzyme activity 
percentage determined at fixed dose of 50 μM (5% DMSO) with respect to 
DMSO. The results reported are the means ± SD determined for at least two 
separate experiments. 
Compound % residual activity hKDM4A 
EML586 38,7 ± 8,4 
EML621 19,7 ± 8,1 
EML622 19,8 ± 7,8 
EML623 4,8 ± 16,0 
EML625 no inhibition 




Removal of hydroxamic acid group in compounds EML625 and EML626 
resulted in a complete loss of activity, thus  On the contrary, quinoline and 
naphthalene derivatives showed a better inhibitory activity against hKDM4A than 
EML586. In particular, the number of nitrogen atoms in the cycle on the right-side 
appeared to be not essential for the activity. In fact, the derivative with a naphthyl 
substituent was more active than the corresponding quinolyl-substituted analogues 
and even more active than the starting quinoxaline hit. 
 
4.3.3. Binding hypothesis and design of new derivatives  
These data are in agreement with crystallographic studies that identified an 
aliphatic subpocket adjacent to the active site in KDM4s extending into the 
substrate binding groove (see Paragraph 1.7)136. It is probable that the naphthyl 
substituent fits into this pocket. 
According to these preliminary SARs and with the aim to investigate the 
effects on potency induced by substitution of quinoxaline-ring in compound 
EML586, we designed a small library of novel analogues planning to replace the 
quinoxaline ring with more lipophilic functions (Figure 4.7). 
 




Novel derivatives were synthesized according to the previously reported 
procedures using a pool of selected aldehydes. We chose both short- and long-chain 
aldehydes, always characterized by variously functionalized aromatic rings, in 
order to explore a wide range of the lipophilic, electronic and steric properties 
(Figure 4.8). 
 
Figure 4.8. Novel library of derivative compounds for lead optimization. 
 
4.4. Biochemical evaluation 
All derivatives have been synthesized according to procedures described in 
Chapter 3 and then screened against hKDM4A using the AlphaLISA homogeneous 
proximity immunoassay.  
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To enhance the robustness of the results, firstly solubility of all derivatives 
has been evaluated both in water and in the assay buffer, using a nephelometer 
according to published procedures137-138.  
 
4.4.1. Determination of solubility 
In drug discovery, solubility is an important parameter to take into account 
because compounds must be dissolved to undergo pharmacological processes. 
Precipitation decreases the concentration in solution, resulting in a reduction of 
compound to bind to the protein of interest. If the compound is partially dissolved 
or is supersaturated, the SARs, pharmacokinetics or in vivo potency may be 
unreliable139. Considering the lipophilic character of novel derivatives, the 
solubility of them has been evaluated before the biochemical assays.  
Solution conditions may largely affect this parameter. Solubility is 
determined by the interactions of the molecules with themselves in the crystal, the 
interactions with themselves in solution, and by the interactions of solute and 
solvent molecules in solution. For these reasons, the measure of solubility under the 
assay conditions has been considered crucial to assist data interpretation139. Thus, 
solubility has been evaluated both in water and in AlphaLISA buffer solution using 
a a nephelometric assay. 
This method measures the intensity of scattered visible light, the light 
reflected by illuminated suspended particles, in a given medium in order to 
determine concentration, size, and shape of disperse particles in disperse systems. 
For light scattering measurements, a signal-to noise ratio (S/N) equals to or >3 was 
used to indicate the presence of precipitation. 
Solubility has been measured at the fixed dose of 25 μM, with the 5% of 
DMSO in both the experimental conditions (water and AlphaLISA buffer). 
Measures have been done immediately after the preparation of samples and after an 
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Figure 4.9. Solubility in water and AlphaLISA buffer. Two incubation times were examined: 0 and 60 minutes. Insoluble compounds are 




As expected, several derivatives showed a poor solubility profile in pure 
water, which decreases in a time-dependent manner. However, all derivatives have 
been found soluble in AlphaLISA buffer at the concentration of 25 μM (5% 
DMSO).   
 
4.4.2. AlphaLISA homogeneous proximity immunoassay 
All synthesized compounds were screened against hKDM4A using the 
AlphaLISA homogeneous proximity immunoassay. 
In agreement to solubility data and expecting a better activity of novel 
compounds with respect to those of the first library, we selected a fixed 25 μM (5% 
DMSO) concentration as cut-off for the biochemical activity evaluation. The results 





















































































































































































Figure 4.10. AlphaLISA assay performed with the hKDM4. Enzyme activity 
percentage determined at 25 μM (5% DMSO) with respect to DMSO.  The results 
reported are the means ± SD determined for at least three separate experiments. 
 
Most active compounds were selected and their activity has been measured 
over a range of concentrations from which IC50 values were determined (Table 4.5). 
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 Table 4.5. Compounds were tested in 10-dose IC50 mode with threefold serial 
dilutions starting at 200 μM (5% DMSO). The results reported are the means ± 
SD determined for at least two separate experiments. 
Compound IC50 (μM) 
EML586 39.7 ± 1.1 
EML621 30.5 ± 1.1 
EML622 37.7 ± 1.1 
EML623 38.2 ± 1.1 
EML624 33.0 ± 1.1 
EML649 140.0 ± 1.2 
EML678 20.8 ± 1.2 
EML682 20.4 ± 1.3 
EML684 22.7 ± 1.3 
 
The data suggested that derivatives with more bulky and lipophilic 
substituents were endowed with the highest inhibitory activity. In particular, 
compounds EML678, EML682 and EML684 were about 2-fold more potent than 
EML586 against hKDM4A in this biochemical assay. These data are in agreement 
with the binding hypothesis discussed in Paragraph 4.3.3.  
 
4.5. Biological evaluation 
Pursuing my efforts toward the identification of new interesting molecular 
probes to elucidate the role of KDM4s, I’ve spent a period of six months abroad, as 
a visiting PhD student in the laboratory of Professor Axel Imhof at the Ludwig 
Maximilian University of Munich. At Imhof lab, I had the opportunity to test some 
selected inhibitors in a cell-based assay in order to analyze the effects of them on 
the histone methylation pattern by mass spectrometry. 
At the same time, an independent analysis of histone methylation levels in 
cells by antibody-based methods, after the treatment with inhibitors, has been 
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performed in collaboration with Professor Lucia Altucci of Seconda Università 
degli Studi di Napoli. 
Both the experiments have demonstrated the ability of synthesized 
compounds to affect the level of histone methylation in cells. In the following 
paragraphs, details have been reported. 
 
4.5.1. Analysis of histone modifications by mass spectrometry 
The analysis of histone modifications in cells is normally performed using 
antibody-based methods like immunoblotting, immunoprecipitation, ELISA, or 
immunofluorescence and is constrained by problems, such as specificity, 
availability, limited dynamic range and by problems in detecting multiple 
modifications on different sites at the same time100. Mass spectrometry (MS) 
provides an alternative experimental approach that can address the complexity of 
histone PTMs in single experimental set and overcome some of the limitations of 
antibody-based methods. 
In collaboration with the group of Professor Axel Imhof, we used a well-
established procedure to isolate histones from cells, prepare them for MS analysis 
and interpret the results.  
HEK 293 cell line has been selected as suitable for the treatment. At first, it 
has been chosen to test only three compounds; hit compound EML586, its direct 
analogue EML621, in which only one nitrogen from the quinoxaline ring was 
removed, and the more lipophilic compound EML684, one of the most powerful 
derivatives identified from my biochemical studies, have been selected as starting 
points. Having no idea of correlation between biochemical and biological activities, 
experiments with 4 different concentrations of inhibitors (200, 100, 50 and 25 μM, 
with final 0.5% DMSO concentration) have been performed and compared to a 
control (0.5% DMSO).  
After an incubation time of 24 h at 36 °C, treated cells were collected and 
histones were isolated from biological tissues by acid extraction. The extraction 
was performed using hydrochloric acid (HCl), due to histones basicity140, starting 
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with whole cells to minimize losses due to handling. Further separation by SDS-
PAGE gel and Coomassie staining showed a characteristic pattern of histones, that 
were isolated from the other basic proteins. The corresponding bands were excised 
from the gel to undergo protease digestion prior to MS analysis. Digestion was lead 
using trypsin to cut proteins in smaller peptides. To avoid generation of peptides 
too short that cannot be analyzed efficiently by MS (trypsin cleave proteins after 
lysine and arginine, very abundant in histone tails), a treatment with propionic 
anhydride was performed to block lysines from tryptic cleavage. Un-methylated 
and mono-methylated lysines react to form propionic amides that are not recognized 
by trypsin, as well as di- and tri-methylated lysines.  
After digestion, the peptides were released from the gel pieces into the 
supernatant through different chemicals and prepared for MS analysis. Samples 
were concentrated and the peptide mixtures were desalted by reversed phase 
absorption/elution.  
Samples were then separated by C18 reversed phase chromatography and the 
eluting peptides were directly ionized and infused into the mass spectrometer, 
which measures the mass-to-charge ratio (m/z) of them. 
Data generated by MS-analysis are summarized in Figure 4.11. 
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Figure 4.11.  H3K9 and H3K27 methylation levels in treated HEK293 compared to control. The results reported are the means ± SD 





The treatment with inhibitors resulted in a dose-dependent increase of methyl 
marks H3K9me3 and H3K27me3 in HEK 293 cells compared to a control group. If 
the increase in H3K9 methylation is in agreement with the inhibition of KDM4 
enzymes, a different state of H3K27 methylation may be associated with the 
inhibition of one or more different JHDM enzymes (i.e. KDM6 subfamily). 
Curiously, these 2 effects appear to occur at the same concentrations. 
Similarly to what we observed in the biochemical assay, the trend of cellular 
activity could be related to the lipophilicity of substituents on the 
dihydroquinazolinone moiety, with compound EML684 being more active then 
EML621 and EML586, respectively. Moreover, despite the methylation levels 
never exceeded a certain threshold, EML684 seemed to completely inhibit the 
enzymatic activity at concentration of 25 μM, suggesting that lower concentrations 
may also be effective. Using this concentration as cut-off, the inhibiting capability 
of other 12 molecules (EML622, EML624, EML645, EML646, EML652, 
EML655, EML657, EML659, EML678, EML683, EML685 and EML686) 
against JHDMs was tested in HEK 293 cell line (Figure 4.12).  
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Figure 4.12. H3K9 methylation levels in treated HEK 293 compared to control. 






Treatment with compounds EML624, EML645, EML646, EML678 and 
EML683 increased H3K9me3 and H3K27me3 levels in a comparable manner to 
that of EML684. 
 
4.5.2. Cell cycle analysis 
To better understand the effects of these compounds in cell-based assays, cell 
viability experiments has been conducted in parallel with MS-analysis using the 
Trypan blue assay. Interestingly, it was observed that inhibitors induced a 
concentration-dependent loss in cellular viability at the same dose that led to 
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Figure 4.13. Cells vitality percentage measured with trypan blue assay at different 
concentration with respect to DMSO.  The results reported are the means ± SD 





 To further investigate treatment-induced cell death, cell cycle analysis has 
been performed by FACS on HEK 293 cells treated with inhibitors. Flow cytometry 
analysis showed an increase in the percentage of cells blocked in S phase and a 
























































































































































Figure 4.14. FACS analysis data for HEK 293 cells treated with inhibitors at 
different concentration with respect to DMSO.  The results reported are the means 
± SD determined for at least two separate experiments.  
As for the effect on the cellular viability, S-block was present only at the 
concentrations that led to reduction of the methylation level, suggesting that there 
may be a correlation between them.   
 




A second biological screening, on a different cell line, was carried out in 
collaboration with Professor Altucci of Seconda Università di Napoli (Naples, 
Italy).  
The effects of compounds EML621, EML622, EML652, EML683 and 
EML685 on cellular histone methylation have been investigated using 
modification-specific antibodies against H3K9me3, H3K9me2 and H4 in human 
colon cancers cells HCT-116. Cells were incubated for the 24 h with the inhibitors 
(50 μM, 0.1% DMSO) and the histone extracts were then immunoblotted with 
antibodies to specific histone acetylation sites (Figure 4.15).  
 
Figure 4.15. Western blot analyses performed with inhibitors at 50 μM for 24 h on the 
methylation of the specific lysine residues H3K9 in histone extracts from HCT-116 cells. 
Methylation was detected by immunoblotting with antibodies specific for histone 
methylation sites as indicated. Total histone H4 was used to check for equal loading. 
PKF118-310 (1 μM) was used as a reference compound. 
 
It was observed that all compounds, in particular EML683, induced a marked 















‘Readers’, ‘writers’, and ‘erasers’ are the mediators of epigenetic mechanisms 
in physiological and disease conditions. Fine-tuning their activity is the goal of 
epigenetic drug discovery, and huge advances are continually being made. While 
HDAC inhibitors are already in clinical use, the understanding of methylation 
regulators has lagged somewhat behind. The scientific community shares the view 
that histone methylation is one of the major crossroads in gene expression and 
regulation. However, the finer features of players involved in molecular machinery, 
known collectively as demethylase enzymes, are yet to be clarified. Investigators 
are looking for small molecules able to modulate these enzymatic families.  
Among demethylases, KDM4 enzymes play an important role in regulation 
of H3K9 and H3K36 methylation, key events for active gene transcription. The 
aberrant activity of these enzymes has being significantly implicated in cancer 
initiation and progression and, as a consequence, they are currently one of the main 
targets investigated in drug discovery. However, only a few inhibitors have been 
identified to date, most of them inhibiting many other Fe(II)/2OG dependent 
oxygenases or being affected by undesirable characteristics, such as poor cell 
permeability, which limit their applicability as chemical probes and their potential 
therapeutic development. Potent and selective inhibitors are, therefore, highly 
needed. 
Starting from a preliminary HTS campaign using an indirect fluorescence 
assay for human KDM4 (hKDM4) subfamily, and the subsequent hit validation 
stage using a more reliable method based on LC-MS and MALDI-TOF, we were 
able to identify a cell-permeable compound, namely EML586, as a promising lead 
candidate for the development of a new series of KDM4 inhibitors. A small library 
of derivatives was then synthesized and tested against hKDM4A compared to the 
lead compound using an AlphaLISA homogeneous proximity immunoassay. 
Cytopermeability was also assessed using a parallel artificial membrane 
permeability assay (PAMPA). This  led us to generate a binding mode hypothesis, 
which posited that hydroxamic acid function cannot be replaced, suggesting the 
possibility of an active role in the formation of coordination bonds with Fe(II). On 
the contrary, replacement of quinoxaline ring with more lipophilic functions 




aliphatic subpocket adjacent to the active site in KDM4s. These data are in 
agreement with crystallographic studies performed by other groups,136 that 
identified an aliphatic subpocket adjacent to the active site in KDM4s extending 
into the substrate binding groove. 
Subsequent derivatization of the 3-hydroxy-2,3-dihydroquinazolin-4(1H)-
one moiety with variously functionalized aromatic rings resulted in the discovery 
of potent inhibitors EML678 and EML684, which showed a better activity against 
hKDM4A compared to the lead compound in the AlphaLISA homogeneous 
proximity immunoassay.  
Then, to better characterize the activity profile of the compounds and analyze 
the effects on histone modifications avoiding the typical issues occurring with 
antibody-based methods (specificity, availability, limited dynamic range and 
problems in detecting multiple modifications on different sites at the same time100), 
we tested the selected molecules in a cell-based assay to analyze the effects on the 
histone methylation pattern through a MS-based method. We found that the 
treatment with the selected inhibitors enables simultaneous and dose-dependent 
increases in levels of H3K9me2/3 and H3K27me2/3 in HEK 293 and HCT116 
colon cancer cells. Further experiments are ongoing, in order to determine the IC50 
values and selectivity profiles over other 2OG-dependent oxygenases and epi-
enzymes. In fact, if the increase in H3K9 methylation is in agreement with the 
inhibition of KDM4s, a different state of H3K27 methylation could be related to a 
downregulation of one or more different JHDM enzymes (i.e. KDM6 subfamily) as 
well as to compensatory effects related to other mechanism, such as an upregulation 
of methyltransferases (HMTs). Furthermore, cytometric analysis also showed that 
these compounds led to a marked arrest in the S phase of cell cycle and a 
concentration-dependent loss in cellular viability. The mechanism of this effects 
and their correlation with the increase of methylation level are still unknown and 
will be subjects of further studies.  
These results are promising and stimulate our research toward the 
identification of even more potent, cell permeable, and selective inhibitors of the 




biology and to further explore the potential of such compounds as anticancer agents. 
The advantage of using such inhibitors for cancer treatment may lie in their ability 
to achieve a synergistic effect in combination with other methylation regulators, 
such as (for example) the inhibitor of KDM6B GSK-J4141. This evidence highlights 
the growing interest to develop combination therapies as viable approaches to 
increase the effectiveness of a histone methylation modulator. Since several 
aberrant histone modifications are involved in cancer, the effect of combination 
therapy is synergistic, targeting simultaneously 2 or more epi-modifications. In 
addition, combo-therapies are useful to overcome drug resistance and minimize 
toxicities and side effects. 
Future efforts will be directed towards two main objectives. The first will be 
the chiral resolution of the most active derivatives, obtained as a mixture of 
enantiomers from the coupling between 2-amino-N-hydroxybenzamide and achiral 
aldehydes, in order to assess which enantiomer is more active. The second aim will 
be the decoration of the left side of our scaffold. With the aim to improve the 
occupation of the enzyme catalytic site, including the binding site of the methylated 
lysine substrate, and consequently increase selectivity, the left side will decorate 
















6.1. General information 
All chemicals were purchased from Sigma Aldrich (Milan, Italy) or from 
Fluorochem Ltd (Hadfield, United Kingdom) and were of the highest purity. All 
solvents were reagent grade and, when necessary, were purified and dried by 
standard methods. All reactions requiring anhydrous conditions were conducted 
under a positive atmosphere of nitrogen in oven-dried glassware. Standard syringe 
techniques were used for anhydrous addition of liquids. Reactions were routinely 
monitored by TLC performed on aluminum-backed silica gel plates (Merck DC, 
Alufolien Kieselgel 60 F254) with spots visualized by UV light (λ = 254, 365 nm) 
or using a KMnO4 alkaline solution. Solvents were removed using a rotary 
evaporator operating at a reduced pressure of∼10 Torr. Organic solutions were 
dried over anhydrous Na2SO4. Chromatographic purification was done on an 
automated flash chromatography system (IsoleraOne™, Biotage) using cartridges 
packed with KP-SIL, 60 Å (40−63 μm particle size). High performance liquid 
chromatography (HPLC) was performed on a Shimadzu SPD 20A UV/vis detector 
(λ = 220 nm) using C-18 column Phenomenex Synergi Fusion RP 80A (75mm × 
4.60 mm; 4 μm) at 25 °C using a mobile phase A (water + 0.1% TFA) and B (MeCN 
+ 0.1% TFA) at a flow rate of 1 mL/min. Melting points were determined on a 
Stuart SMP30 melting point apparatus in open capillary tubes and are uncorrected. 
1H NMR spectra were recorded at 300 MHz on a Bruker Avance 300 spectrometer 
or at 400 MHz on a Bruker AVANCE III HD. Chemical shifts are reported in δ 
(ppm) relative to the internal reference tetramethylsilane (TMS). When compounds 
were tested as salts, NMR data refer to the free base. Mass spectra were recorded 
on a Finnigan LCQ DECA TermoQuest (San Jose, USA) mass spectrometer in 
electrospray positive and negative ionization modes (ESI-MS). Purity of tested 
compounds was established by combustion analysis, confirming a purity ≥95%. 
 
6.2. Procedures to obtain thiophene-2-sulfonamide derivatives 
Synthesis of ethyl 5-(N-(tert-butyl)sulfamoyl)thiophene-2-carboxylate 
and 2-((5-(ethoxycarbonyl)thiophene)-3-sulfonamido)-2-methylpropan-1-





To a stirred solution of ethyl thiophene-2-carboxylate (98; 1.00 g, 6.40 mmol) 
in DCM (15.0 mL), chlorosulfonic acid (14.0 mL) was added slowly. The reaction 
mixture was stirred at room temperature overnight, then was poured in water (200 
mL) at 0 °C and extracted with CH3Cl (3 x 70 mL). The organic phase was dried 
(Na2SO4), filtered, and concentrated in vacuo. The residue was dissolved in dry 
THF (10 mL) then tert-butylamine (1.87 g, 25.60 mmol) was added to stirring 
solution. The resulting white suspension was stirred vigorously for 1 h, then the 
reaction mixture was taken up with EtOAc (100 mL), washed with saturated 
aqueous solution of NaHCO3 (3 x 30 mL) and  brine (30 mL), dried, filtered, and 
concentrated in vacuo. The crude was purified by silica gel chromatography 
(DCM/EtOAc) to give the title compounds in ratio 1:1 in 60% yield as a brown oil.  
1H NMR (300 MHz, CDCl3) δ 8.11 (s, 1H), 8.01 (s, 1H), 7.70 (d, J = 3.9 Hz, 1H), 
7.57 (d, J = 3.9 Hz, 1H), 4.49 – 4.37 (m, 5H), 1.35 (d, J = 3.2 Hz, 16H), 1.31 (s, 
7H). MS ESI m/z: 292 [M + H]+. 
  Synthesis of ethyl 4-(chlorosulfonyl)thiophene-2-carboxylate and ethyl 
5-(chlorosulfonyl)thiophene-2-carboxylate (101a-b) 
To a stirred solution of ethyl 5-(chlorosulfonyl)thiophene-2-carboxylate and 
ethyl 4-(chlorosulfonyl)thiophene-2-carboxylate mixture (0.50 g, 1.71 mmol) in 
THF (5 mL) was added a lithium hydroxide water solution (5 mL, 1.4 M). The 
resulting mixture was stirred overnight at room temperature. The organic solvent 
was evaporated and resulting aqueous solution was washed with DCM (3 x 2 mL). 
The crude was recovered by acidification of the aqueous phase with HCl 12 N and 
filtration of the white precipitate. Final purification by preparative HPLC allowed 
us to obtain all of the designed compounds in quantitative yield.  





1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 3.9 Hz, 1H), 7.58 (d, J = 3.9 Hz, 
1H), 4.79 (s, 1H), 1.33 (s, 9H). MS ESI m/z: 264 [M + H]+. 
4-(N-(tert-butyl)sulfamoyl)thiophene-2-carboxylic acid 101b 
 
1H NMR (300 MHz, CDCl3) δ 8.79 (s, 1H), 8.38 – 8.25 (m, 1H), 4.59 (d, J = 
7.1 Hz, 1H), 1.48 (t, J = 7.1 Hz, 9H). MS ESI m/z: 264 [M + H]+. 
General procedure for the synthesis of N-(tert-butyl)-5-(4-(pyridin-2-
ylmethyl)piperazine-1-carbonyl)thiophene sulfonamides 94a-b 
To a stirring solution of thiophene carboxylic acid (101a-b; 0.30 g, 1.15 
mmol), 1-(pyridin-2-ylmethyl)piperazine (102; 0.11 g, 0.95 mmol) and N,N-
dimethylpyridin-4-amine (0.01 g, 0.10 mmol) in dry DCM (15.0 mL) was added 
N,N'-methane Diylidene dicyclohexanamine. The mixture was stirred at room 
temperature overnight. The white precipitate was removed by filtration and the 
crude was readily purified by silica gel chromatography (DCM/MeOH) to give the 







1H NMR (300 MHz, DMSO-d6) δ 8.50 (d, J = 3.9 Hz, 1H), 7.90 (s, 1H), 7.78 
(t, J = 7.0 Hz, 1H), 7.58 – 7.42 (m, 2H), 7.36 (d, J = 3.6 Hz, 1H), 7.30 – 7.23 (m, 




1H NMR (300 MHz, DMSO-d6) δ 8.84 (d, J = 4.0 Hz, 1H), 8.60 (s, 1H), 8.12 
(t, J = 7.2 Hz, 1H), 7.88 (s, 1H), 7.85 – 7.76 (m, 2H), 7.68 – 7.56 (m, 1H), 3.99 (s, 
6H), 1.45 (s, 9H). MS ESI m/z: 423 [M + H]+. 
General procedure for the synthesis of 5-(4-(pyridin-2-
ylmethyl)piperazine-1-carbonyl)thiophene sulfonamides 95a-b 
To a stirring solution of sulfonamide (94a-b; 0.11 g, 0.27 mmol) in DMC (5.0 
mL) was added trifluoroacetic acid (5.0 mL). The mixture was stirred at room 
temperature overnight. After the evaporation of the solvent, water (20 mL) was 
added and title compound was extracted with EtOAc (3 x 7 mL), washed with brine 
(10 mL), dried, filtered, and concentrated in vacuo. The desired product was 







1H NMR (300 MHz, DMSO-d6) δ 8.68 (d, J = 5.0 Hz, 1H), 7.94 (t, J = 7.6 
Hz, 1H), 7.86 (s, 2H), 7.65 – 7.50 (m, 4H), 4.40 (s, 2H), 3.88 (s, 4H). MS ESI m/z: 




1H NMR (300 MHz, DMSO-d6) δ 8.68 (d, J = 4.4 Hz, 1H), 8.27 (s, 1H), 7.94 
(t, J = 7.7 Hz, 1H), 7.65 (s, 1H), 7.59 – 7.37 (m, 4H), 4.43 (s, 2H), 3.89 (s, 4H). MS 
ESI m/z: 367 [M + H]+. 
General procedure for the synthesis of N-((5-(4-(pyridin-2-
ylmethyl)piperazine-1-carbonyl)thiophenyl) sulfonyl)pivalamides (96a-b) 
To a stirring suspension of sulfonamide (95a-b; 0.12 g, 0.26 mmol) in dry 
DMC (6.0 mL) were added, in this order, triethylamine (0.05 g, 0.52 mmol) and 
pivaloyl chloride (0.04 g, 0.31 mmol). The yellow solution thus obtained was stirred 
at room temperature overnight. After the removal of solvent under reduced 
pressure, crude was purified by silica gel chromatography (DCM/MeOH) to give 







1H NMR (300 MHz, DMSO-d6) δ 11.68 (s, 1H), 8.52 (s, 1H), 8.41 (s, 1H), 
7.79 (s, 1H), 7.54 (s, 1H), 7.47 (d, J = 7.6 Hz, 1H), 7.29 (s, 1H), 3.65 (s, 6H), 1.05 




1H NMR (300 MHz, CDCl3) δ 8.60 – 8.44 (m, 1H), 7.71 (d, J = 4.0 Hz, 1H), 
7.65 – 7.53 (m, 1H), 7.31 (d, J = 7.8 Hz, 1H), 7.18 (s, 1H), 7.12 (dd, J = 8.2, 4.5 
Hz, 2H), 3.66 (d, J = 11.8 Hz, 6H), 1.10 (d, J = 2.1 Hz, 9H). MS ESI m/z: 451 [M 
+ H]+. 
6.3. Procedures to obtain quinoxaline derivative (97) 
Synthesis of N-(tert-butyl)-4-chloro-3-nitrobenzenesulfonamide 104 
 
A slurry of 1-chloro-2-nitrobenzene (103; 2.00 g, 12.69 mmol) and 
chlorosulfonic acid (10.0 mL) was stirred at 150 °C for 8 h. The mixture was poured 
in water (200 mL) and chloride derivative was extracted with EtOAc (3 x 75 mL), 
washed with brine (10 mL), dried, filtered, and concentrated in vacuo. Crude 
intermediate was dissolved in dry THF (10.0 mL) then triethylamine (5.13 g, 50.76 
mmo) was added. Orange suspension was stirred at room temperature for 1 h, after 
that solvent was removed un reduced pressure. Crude mixture was dissolved in 
EtOAc (100 mL) and organic phase was washed with water (3 x 30 mL) brine (30 
mL), dried, filtered, and concentrated in vacuo. Pure compound was recovered 




1H NMR: (300 MHz, DMSO-d6) δ 8.47 (d, J = 1.0 Hz, 1H), 8.09 (dd, J = 8.4, 
1.2 Hz, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.94 (s, 1H), 1.13 (s, 9H). MS ESI m/z: 293 




A 40 mL CEM pressure vessel equipped with stirrer bar was charged with 
intermediate 104 (1.12 g, 3.81 mmol), propargylamine (105; 0.39 mL, 6.10 mmol), 
triethylamine (0.77 mL, 5.53 mmol) and ethanol (20 mL). The microwave vial was 
sealed and heated in a CEM Discover microwave synthesizer to 120 °C (measured 
by the vertically focused IR temperature sensor) for 1.5 h. After cooling to room 
temperature, solvent was removed and crude was purified by silica gel 
chromatography (Hex/EtOAc) to give the title compounds in 65% yield as a orange 
solid.  
1H NMR (300 MHz, DMSO-d6) δ 8.72 (t, J = 5.3 Hz, 1H), 8.48 (d, J = 2.0 
Hz, 1H), 7.92 (dd, J = 9.0, 1.7 Hz, 1H), 7.54 (s, 1H), 7.25 (d, J = 9.1 Hz, 1H), 4.29 
(dd, J = 5.3, 1.7 Hz, 2H), 3.28 (d, J = 2.0 Hz, 1H), 1.11 (s, 9H). MS ESI m/z: 312 




A boiling solution of the intermediate 106 (1.34 g, 4.31 mmol) in ethanol (20 
ml) was added to a suspension of iron(II) sulfate heptahydrate (12.0 g, 43.1 mmol) 
in water (20.0 ml) and 32% ammonium hydroxide (2.0 ml). The reaction mixture 




ml). The hot mixture was filtered and the inorganic material was washed with 
boiling ethanol. The solution was partially evaporated and then extracted with 
chloroform (3 x 100 ml). The combined organic layers were washed with water 
followed by a saturated sodium chloride solution, dried over anhydrous sodium 
sulfate and evaporated to give pure compound 107 without any other purification 
in 90% yield (yellow solid).  
1H NMR (300 MHz, DMSO-d6) δ 7.05 – 6.92 (m, 3H), 6.56 (d, J = 8.9 Hz, 
1H), 5.55 (t, J = 5.4 Hz, 1H), 4.90 (s, 2H), 3.96 (dd, J = 5.4, 2.0 Hz, 2H), 3.13 (t, J 
= 2.0 Hz, 1H), 1.07 (s, 9H). MS ESI m/z: 282 [M + H]+. 
Synthesis of N-(tert-butyl)-3-methylquinoxaline-6-sulfonamide 108 
 
Intermediate 107 (0.09 g, 0.32 mmol) and tetrakis(acetonitrile)copper(I) 
tetrafluoroborate (0.10 g, 0,03 mmol) were suspended in toluene (5.0 mL) in a close 
vessel and mixture stirred at 90 °C for 11 h. The hot mixture was filtered through 
Celite and the crude was purified by silica gel chromatography (Hex/EtOAc) to give 
the title compounds in 67% yield as brown solid.  
1H NMR (300 MHz, DMSO-d6) δ 8.99 (s, 1H), 8.38 (s, 1H), 8.24 (d, J = 8.9 
Hz, 1H), 8.12 (d, J = 8.9 Hz, 1H), 7.88 (br s, 1H), 2.75 (s, 3H), 1.11 (s, 9H). MS 
ESI m/z: 280 [M + H]+. 
Synthesis of N-(tert-butyl)-3-formylquinoxaline-6-sulfonamide 109 
 
To a hot suspension of selenium dioxide (0.08 g, 0.72 mmol) in dioxane (1.5 
mL) was added a solution of compound 108 (0.10 g, 0.36 mmol) in dioxane (0.5 




and the crude was purified by silica gel chromatography (Hex/EtOAc) to give the 
title compounds in 81% yield as reddish solid. 
1H NMR (300 MHz, DMSO-d6) δ 10.20 (s, 1H), 9.45 (s, 1H), 8.72 – 8.24 (m, 
3H), 8.03 (s, 1H), 1.14 (s, 9H). MS ESI m/z: 294 [M + H]+. 
Synthesis of 2-((tetrahydro-2H-pyran-2-yl)oxy)isoindoline-1,3-dione 
129b 
 
To a stirring solution of N-hydroxyphthalimide 126 (10.00 g, 61.30 mmol) in 
DCM/dioxane (250.0 mL, ratio 4:3) were added 3,4-dihydro-2H-pyran (128; 6.70 
g, 79.69 mmol) and para-toluenesulfonic acid monohydrate (0.23 g, 1.23 mmol). 
The reaction mixture was stirred at room temperature for 3.5 h. Saturated aqueous 
solution of NaHCO3 (200 mL) was added to the reaction mixture and organic layer 
was separated. The aqueous layer was further extracted with DCM (2 x 70 mL) and 
the combined organic phase was washed with water followed by a saturated sodium 
chloride solution, dried over anhydrous sodium sulfate and evaporated to give pure 
compound 129b as a white solid (99%).  
1H NMR (300 MHz, DMSO-d6) δ 1.62–1.64 (3H, m), 1.77–1.81 (2H, m), 
1.91–1.93 (1H, m), 3.58 (1H, d, J=10.2 Hz), 4.28–4.33 (1H, m), 5.32 (1H, s), 7.88 
(4H). MS ESI m/z: 118 [M+H]+. 
Synthesis of O-(tetrahydro-2H-pyran-2-yl)hydroxylamine 123b 
 
To a stirring solution of compound 129b (15.00 g, 61.30 mmol) in Et2O 
(150.0 mL) was added hydrazine monohydrate (6.20 g, 110.60 mmol). The mixture 
was stirred at room temperature for 2 h. The white precipitate was removed by 




controlled pressure to afford compound 123b as a yellow oil (99%), which was used 
for the next steps without further purification.  
1H NMR (300 MHz, DMSO-d6) δ 5.99 (2H, s), 4.56–4.57 (1H, m), 3.73–3.80 
(1H, m), 3.40–3.46 (1H, m), 1.54–1.65 (2H, m), 1.43–1.44 (4H, m). MS ESI m/z: 
248 [M+H]+. 
Synthesis of 2-amino-N-((tetrahydro-2H-pyran-2-yl)oxy)benzamide 
124b 
 
A suspension of isatoic anhydride (122; 5.00 g, 30.66 mmol) and 
hydroxylamine 123b (7.18 g, 61.32 mmol) in ACN (45.0 mL) was refluxed for 2 h 
and then concentrated in vacuo. The residue was treated with EtOAc (100.0 mL) 
and washed with water (3 x 30 mL) saturated sodium chloride solution (30.0 mL). 
The organic layer was dried over anhydrous sodium sulfate and evaporated. 
Compound 124b was collected as white solid (90%) after recrystallization from 
toluene.  
1H NMR (300 MHz, DMSO-d6) δ 7.35 (d, J = 7.9 Hz, 1H), 7.15 (t, J = 7.7 
Hz, 1H), 6.70 (d, J = 8.3 Hz, 1H), 6.49 (t, J = 7.5 Hz, 1H), 6.23 (s, 2H), 4.96 (s, 
1H), 1.71 (m, 3H), 1.54 (m, 3H); MS ESI m/z: 237 [M+H]+. 
Synthesis of 2-amino-N-hydroxybenzamide 33 
 
To a solution of compound 127b (6.00 g, 25.39 mmol) in MeOH (50.0 mL) 
was added the resin Amberlyst® 15 hydrogen form wet (3.00 g, 1.7 meq/mL by 
wetted bed volume). The resulting solution was gently stirred at 50 °C for 3.5 h. 




pressure. Pure compound 33 was collected as white solid (95%) after 
recrystallization from toluene.  
1H NMR (300 MHz, DMSO-d6) δ 10.70 (s, 1H), 8.85 (s, 1H), 7.30 (dd, J = 
7.9, 1.6 Hz, 1H), 7.12 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H), 6.69 (dd, J = 8.3, 1.2 Hz, 1H), 
6.52 – 6.43 (m, 1H), 6.22 (s, 2H); MS ESI m/z: 153 [M+H]+. 
Synthesis of N-(tert-butyl)-3-hydroxy-4-oxo-2-(quinoxalin-2-yl)-1,2,3,4-
tetrahydroquinazoline-7-sulfonamide 97  
 
To a solution of 2-amino-N-hydroxybenzamide (33; 0.10 g, 0.66 mmol) in 
methanol (5.0 mL) was added quinoxaline (109; 0.11 g, 0.73 mmol). The mixture 
was stirred at room temperature for 2 h, then the solvent was removed in vacuo. 
The crude was readily purified by silica gel chromatography (DCM/MeOH) to give 
the title compound as reddish solid. 
1H NMR (300 MHz, DMSO-d6) δ 9.97 (s, 1H), 9.24 (d, J = 1.5 Hz, 1H), 8.40 
(s, 1H), 8.33 (d, J = 8.8 Hz, 1H), 8.22 (d, J = 8.9 Hz, 1H), 7.92 (s, 1H), 7.74 (d, J = 
7.9 Hz, 1H), 7.67 (s, 1H), 7.27 (t, J = 7.2 Hz, 1H), 6.77 (t, J = 7.6 Hz, 1H), 6.70 (d, 
J = 8.2 Hz, 1H), 6.28 (s, 1H), 1.11 (s, 9H). MS ESI m/z: 428 [M+H]+. 
 
6.4. Procedures to obtain triazole derivatives  
General procedure for the synthesis of thiobiureas 82a-e 
To a suspension of sodium acetate (0.22 g, 2.63 mmol) and semicarbazide 
(0.29 g, 2.63 mmol) in acetonitrile (10.0 mL) was added the proper isothiocyanate 
81a-e (2.63 mmol), and the reaction mixture was stirred for 24 h. The solvent was 
removed by rotary evaporation, and the resulting residue was dissolved in 2 M 
NaOH aqueous solution (30 mL) and filtered through activated charcoal to remove 




precipitate was collected and washed with water (3 × 20 mL) and hexanes (2 × 20 
mL) to afford the title compound as a white solid (95%). 
2-(cyclopropylcarbamothioyl)hydrazine-1-carboxamide 82a 
 
1H NMR (300 MHz, DMSO-d6) δ 9.07 (s, 1H), 7.89 (s, 1H), 7.76 (s, 1H), 
5.93 (s, 2H), 3.00 (s, 1H), 1.39 – 0.28 (m, 4H). MS ESI m/z: 175 [M+H]+. 
2-(phenylcarbamothioyl)hydrazine-1-carboxamide 82b 
 
1H NMR (300 MHz, DMSO-d6) δ 9.63 (s, 1H), 9.38 (s, 1H), 8.01 (s, 1H), 
7.52 (d, J = 7.3 Hz, 1H), 7.31 (t, J = 7.8 Hz, 2H), 7.13 (t, J = 7.3 Hz, 1H), 6.04 (s, 
2H). MS ESI m/z: 211 [M+H]+. 
2-((4-methoxyphenyl)carbamothioyl)hydrazine-1-carboxamide 82c 
  
1H NMR (300 MHz, DMSO-d6) δ 12.61 (s, 1H), 7.20 (d, J = 8.5 Hz, 2H), 
7.02 (d, J = 8.9 Hz, 2H), 3.80 (s, 3H). MS ESI m/z: 241 [M+H]+. 
2-(benzylcarbamothioyl)hydrazine-1-carboxamide 82d 
 
1H NMR (300 MHz, DMSO-d6) δ 9.54 (s, 1H), 9.38 (s, 1H), 7.37 – 7.24 (m, 






1H NMR (300 MHz, DMSO-d6) δ 7.83 (s, 1H), 7.58 (s, 1H), 7.21 (d, J = 18.5 
Hz, 6H), 6.22 (s, 2H), 3.77 (t, J = 7.6 Hz, 2H), 2.77 (d, J = 7.6 Hz, 2H). MS ESI 
m/z: 239 [M+H]+.  
General procedure for the synthesis of 3-hydroxy-5-thiol derivatives 78a-
e 
The proper 2-thiobiurea compound 82a-e (1.88 mmol) in 2 M NaOH aqueous 
solution (20.0 mL) was stirred at reflux for 6 h. The reaction mixture was allowed 
to cool to room temperature and then acidified with 1 N HCl. The resulting 
precipitate was collected by filtration and washed with water (3 × 20 mL), hexanes 
(2 × 20 mL), 1:1 hexanes/ diethyl ether (20 mL) successively and dried in vacuo to 
afford the title compound as a white solid (95%).  
4-cyclopropyl-5-mercapto-4H-1,2,4-triazol-3-ol 78a (EML615) 
 
1H NMR (300 MHz, DMSO-d6) δ 2.77 – 2.15 (m, 1H), 1.19 – 0.65 (m, 2H), 
0.65 – 0.34 (m, 2H). MS ESI m/z: 157 [M+H]+. 
5-mercapto-4-phenyl-4H-1,2,4-triazol-3-ol 78b 
 
1H NMR (300 MHz, DMSO-d6) δ 12.77 (s, 2H), 8.01 – 6.47 (m, 5H). MS 






1H NMR (300 MHz, DMSO-d6) δ 7.21 (d, J = 8.5 Hz, 2H), 7.04 (d, J = 8.9 
Hz, 2H), 3.82 (s, 3H). MS ESI m/z: 224 [M+H]+. 
4-benzyl-5-mercapto-4H-1,2,4-triazol-3-ol 78d 
 
1H NMR (300 MHz, DMSO-d6) δ 13.07 (s, 2H), 7.94 – 6.83 (m, 5H), 4.85 
(s, 2H). MS ESI m/z: 208 [M+H]+. 
5-mercapto-4-phenethyl-4H-1,2,4-triazol-3-ol 78e 
 
1H NMR (300 MHz, DMSO-d6) δ 13.03 (s, 2H), 7.74 – 6.86 (m, 5H), 3.85 (t, 
J = 7.8 Hz, 2H), 2.93 (t, J = 7.8 Hz, 2H). MS ESI m/z: 222 [M+H]+. 
Synthesis of phenyl (4-methoxyphenyl)carbamate 85 
 
Phenyl chloroformate (1.72 g, 10.98 mmol) was added dropwise to a stirred 
mixture of p-ethoxyaniline (1.37 g, 9.99 mmol), pyridine (0.85 g, 10.98 mmol) and 
EtOAC (20.0 mL) at 0 °C. The mixture was stirred for 3 h at room temperature, 




The solvent was evaporated under reduced pressure and the deposited solid were 
collected and washed with hexane to give 85 as yellow solid (55%). The product 
can be used directly in the next step without further purification. 
1H NMR (300 MHz, DMSO-d6) δ 10.06 (s, 1H), 7.39-7.44 (m, 4H), 7.19-
7.26 (m, 3H), 6.90 (d, 2H, J = 9.0 Hz), 3.71 (s, 3H). MS ESI m/z: 244 [M+H]+. 
Synthesis of N-(4-methoxyphenyl)hydrazinecarboxamide 86 
 
A mixture of compound 85 (1.80 g, 7.41 mol), 33% hydrazine hydrate (0.74 
mL) and dimethoxyethane (12.0 mL) was stirred for 24 h. The solvent was 
evaporated under reduced pressure and the residue was washed with EtOAc. The 
title compound was collected as a pink solid (90%) after recrystallization from 
ethanol.  
1H NMR (300 MHz, DMSO-d6) δ 8.45 (s, 1H), 7.41 (d, 2H, J = 8.7 Hz), 7.29 
(s, 1H), 8.82 (d, 2H, J = 8.7 Hz), 4.31 (s, 2H), 3.71 (s, 3H). MS ESI m/z: 182 
[M+H]+. 
Synthesis of 4-(4-methoxyphenyl)-4H-1,2,4-triazol-3-ol 79 
 
A mixture of compound 86 (7.56 g, 0.05 mol), formamidine acetate (22.0 g, 
0.2 mol) and DMF (250.0 mL) was stirred at room temperature for 30 min. AcOH 
(15 mL) was added, and the resulting mixture was heated for 8 h at 80 °C. The 
solvent was evaporated under reduced pressure and the residue was poured into the 
ice water. After filtration, the crude was purified by silica gel chromatography 




1H NMR (300 MHz, DMSO-d6) δ 9.69 (s, 1H), 7.73 (d, J = 7.5 Hz, 1H), 7.10 
(d, J = 7.5 Hz, 1H), 3.79 (s, 3H). MS ESI m/z: 192 [M+H]+. 
 
6.5. Procedures to obtain N-(5-ethyl-1-(2-morpholinoethyl)-3-oxoindolin-2-
yl)acetamide  
Synthesis of 5-ethylindoline-2,3-dione 89 
 
To a 60 mL aqueous solution of chloral hydrate (3.60 g, 22.00 mmol) were 
added 52.00 g sodium sulfate, 4-ethylaniline (2.42 g, 20.00 mmol), 2.0 mL HCl 1 
N, and a 20.0 mL aqueous solution of hydroxylamine hydrochloride (4.40 g, 63.00 
mmol), successively. This solution was gradually heated, and refluxed for 1 min. 
Upon cool, the precipitate was filtered. The dark brown solid was added to 20 mL 
surfuric acid at 50 °C in small portions, and heated at 80 °C for 10 min. The 
resulting solution was cooled to room temperature, and dropwise added to ice, and 
the precipitate was filtrated to give title compound as orange solids in 65% yield. 
1H NMR (300 MHz, CDCl3) δ 7.81 (s, 1H), 7.46 (s, 1H), 7.38-7.41 (d, 1H), 
6.81-6.83 (d, 1H), 2.59-2.67 (q, 2H), 1.20-1.25 (t, 3H). MS ESI m/z: 176 [M+H]+. 
Synthesis of 5-ethyl-1-(2-morpholinoethyl)indoline-2,3-dione 91 
 
To a stirring suspension of compound 89 (0.22 g, 1.25 mmol) and potassium 
carbonate (0.22 g, 1.62 mmol) in dry DMF (5.0 mL) was added 2-morpholinoethyl 




mixture was heated at 70 °C overnight and then concentrated in vacuo. The residue 
was treated with EtOAc (100 mL) and washed with saturated aqueous solution of 
NaHCO3 (3 x 30 mL) saturated sodium chloride solution (30 mL). The organic layer 
was dried over anhydrous sodium sulfate and evaporated. The crude was readily 
purified by silica gel chromatography (DCM/MeOH) to give the title compounds 
in 70% yield as a orange oil. 
1H NMR (300 MHz, CDCl3) δ 7.39 (d, J = 8.2 Hz, 2H), 6.83 (dd, J = 7.8, 0.9 
Hz, 1H), 3.81 (t, J = 6.6 Hz, 2H), 3.61 (d, J = 4.7 Hz, 4H), 2.59 (td, J = 7.5, 7.0, 3.8 
Hz, 4H), 2.52 – 2.42 (m, 4H), 1.20 (t, J = 7.6 Hz, 3H). MS ESI m/z: 289 [M+H]+. 
Synthesis of 5-ethyl-3-imino-1-(2-morpholinoethyl)indolin-2-one 92 
 
Compound 91 (0.25 g, 0.83 mmol) and formic acid (0.08 mmol) were stirred 
in a saturated solution of ammonia in methanol (5.0 mL) at room temperature for 3 
h. The mixture was concentrated in vacuo to give the title compound in 80% yield 
as yellowish oil. Due to its poor stability, the product was used directly in the next 
step without further purification. 
1H NMR (300 MHz, CDCl3) δ 7.66 (d, J = 1.8 Hz, 1H), 7.32 – 7.21 (m, 1H), 
6.87 (t, J = 8.6 Hz, 1H), 3.79 (t, J = 6.9 Hz, 2H), 3.73 – 3.58 (m, 2H), 3.48 (s, 2H), 
2.65 (q, J = 7.4 Hz, 2H), 2.49 – 2.33 (m, 4H), 1.95 – 1.75 (m, 2H), 1.56 – 1.06 (m, 







 A solution of compound 92 (0.80 g, 2.78 mmol) in THF (5.0 mL) was 
prepared and cooled to -78 °C, then sodium cyanoborohydride (0.35 g, 5.56 mmol) 
was added. The mixture was stirred at -78 °C for 6 h, then acetic anhydride was 
added. The mixture was allowed to slowly warm to ambient temperature while 
stirring overnight. After the removal of solvent under reduced pressure, the 
resulting residue was dissolved in DCM and washed with saturated aqueous 
solution of NaHCO3 (3 x 30 mL) and brine (30 mL). The organic layer was dried 
over anhydrous sodium sulfate and evaporated. Final purification by preparative 
HPLC allowed us to obtain the title compound in 20% yield as white solid. 
1H NMR (300 MHz, DMSO-d6) δ 9.57 (s, 1H), 8.94 (d, J = 8.0 Hz, 1H), 7.17 
(d, J = 8.2 Hz, 1H), 7.06 (d, J = 7.4 Hz, 1H), 5.08 (d, J = 7.7 Hz, 1H), 4.24 – 3.82 
(m, 4H), 3.77 – 3.48 (m, 4H), 3.48 – 3.27 (m, 2H), 3.27 – 3.02 (m, 2H), 2.57 (q, 
2H), 1.89 (s, 3H), 1.15 (t, J = 7.6 Hz, 3H). MS ESI m/z: 332 [M+H]+. 
 
6.6. Procedure to obtain 3-hydroxy-2,3-dihydroquinazolin-4(1H)-one 
derivatives 
General procedure for the synthesis of alcohol 67a-76a 
A solution of proper aldehyde (54-64; 9.42 mmol) in MeOH (25.0 mL) was 
prepared and cooled to 0 °C, then sodium borohydride (0.72 g, 18.84 mmol) was 
added portionwise. The mixture was allowed to slowly warm to room temperature 
while stirring for 30 min. After the removal of solvent under reduced pressure, the 
resulting residue was dissolved in DCM (50 mL) and washed with water (3 x 15 
mL) and brine (15 mL). The organic layer was dried over anhydrous sodium sulfate 




 Phenylmethanol 67a 
 
Colorless oil, 95% yield. 1H-NMR (300 MHz, CDCl3) δ 7.26 (m, 5H) 4.51(s, 
2H) 3,18 (s, 1H)142. MS ESI m/z: 109 [M+H]+. 
(4-chlorophenyl)methanol 68a 
 
White solid, 98% yield. 1H-NMR (300 MHz, CDCl3) δ 7.26−7.32 (m, 4H), 
4.67 (s, 2H)142. MS ESI m/z:143 [M+H]+. 
(4-nitrophenyl)methanol 69a 
 
Yellow solid, 95% yield. 1H-NMR (300 MHz, CDCl3) δ 8.22 (d, J = 8.4 Hz, 
2H), 7.53 (d, J = 8.4 Hz, 2H), 4.84 (s, 2H)142. MS ESI m/z: 154 [M+H]+.  
(4-methoxyphenyl)methanol 70a 
 
Colorless oil, 98% yield. 1H-NMR (300 MHz, CDCl3) δ 7.23 (d, J = 8.5 Hz, 




Colorless oil, 98% yield. 1H-NMR (300 MHz, CDCl3) δ 7.60 (d, J = 8.4 Hz, 






White solid, 95% yield. 1H-NMR (300 MHz, CDCl3) δ 7.42 (d, J = 1.9 Hz 
1H), 7.39 (d, J = 8.3 Hz 1H) 7.15 (td, J= 8.3 1.9 0.6 Hz 1H), 4.61 (d, J = 0.9 Hz, 
2H)142. MS ESI m/z: 177 [M+H]+. 
(2,4-dichlorophenyl)methanol 73a 
 
White solid, 99% yield. 1H-NMR (300 MHz, CDCl3) δ 7.38 (d, J =8.1 Hz, 
1H), 7.36 (d, J = 2.1 Hz, 1H), 7.25 (dd, J = 8.1 Hz J = 2.1 Hz, 1H), 4.71 (s, 2H), 
2.31 (s, 1H)142. MS ESI m/z: 177 [M+H]+.   
(4-chloro-2-fluorophenyl)methanol 74a 
 
White solid, 98% yield. 1H-NMR (300 MHz, CDCl3) δ 7.38 (t, J = 8.1 Hz, 
1H), 7.15 (dd, J = 8.2, 2.1 Hz, 1H), 7.09 (dd, J = 9.8, 2.0 Hz, 1H), 4.73 (d, J = 4.2 
Hz, 2H), 1.76 (d, J = 6.7 Hz, 1H). MS ESI m/z: 161 [M+H]+. 
(2-chloro-6-fluorophenyl)methanol 75a  
 
Yellowish oil, 98% yield. 1H-NMR (300 MHz, CDCl3) δ 7.45 – 6.94 (m, 1H), 






White solid, 97% yield. 1H-NMR (300 MHz, CDCl3) δ 4.65 (s, 2H), 
7.00−7.04 (m, 2H), 7.29−7.33 (m, 2H)142. MS ESI m/z: 127 [M+H]+. 
General procedure for the synthesis of methanesulfonate derivatives 
67b-76b 
A solution of proper alcohol (67a-76a; 9.42 mmol) in dry DCM (25.0 mL) 
was prepared and cooled to 0 °C, then triethylamine (2.6 mL, 18.84 mmol) and 
mesyl chloride (0.9 mL, 11.30 mmol) were added respectively. The mixture was 
allowed to slowly warm to room temperature while stirring for 3.5 h, then was 
washed with water (3 x 10 mL) and brine (10 mL). The organic layer was dried 
over anhydrous sodium sulfate and evaporated to afford the title compound as 
colorless oil (95-99%) which was used for the next steps without further 
purification. 
General procedure for the synthesis of aldehydes 38-49 
To stirring suspension of proper hydroxybenzaldehyde (55, 65-66; 0.50 g, 
4.10 mmol) and potassium carbonate (1.13 g, 8.20 mmol) in acetone (20.0 mL) was 
added  a solution of proper methanesulfonate derivative (67b-76b; 4.91 mmol) in 
acetone (1 M). The mixture was refluxed for 1 h, then the solvent was removed in 
vacuo, the residue was dissolved in DCM (50 mL) and washed with water (3 x 15 
mL) and brine (15 mL). The organic layer was dried over anhydrous sodium sulfate 
and evaporated. The crude was readily purified by silica gel chromatography 






White solid, 77% yield. 1H-NMR (300 MHz, DMSO-d6) δ 9.87 (s, 1H), 7.87 
(d, J = 8.8 Hz, 2H), 7.50-7.34 (m, 5H), 7.21 (d, J = 8.8 Hz, 2H), 5.23 (s, 2H)143. MS 
ESI m/z: 213 [M+H]+. 
4-((4-chlorobenzyl)oxy)benzaldehyde 39 
 
White solid, 85% yield. 1H-NMR (300 MHz, DMSO-d6) δ 9.87 (s, 1H), 7.88 
(d, J = 8.6 Hz, 2H), 7.56 – 7.43 (m, 4H), 7.20 (d, J = 8.4 Hz, 2H), 5.24 (s, 2H)144. 
MS ESI m/z: 247 [M+H]+.  
4-((4-nitrobenzyl)oxy)benzaldehyde 40 
 
Yellow solid, 79% yield. 1H-NMR (300 MHz, DMSO-d6) δ 9.88 (s, 1H), 8.28 
(d, J = 8.5 Hz, 2H), 7.89 (d, J = 8.6 Hz, 2H), 7.74 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 
8.6 Hz, 2H), 5.42 (s, 2H)144. MS ESI m/z: 258 [M+H]+. 
4-((4-methoxybenzyl)oxy)benzaldehyde 41 
 
White solid, 84% yield. 1H-NMR (300 MHz, DMSO-d6) δ 9.86 (s, 1H), 7.86 
(d, J = 8.7 Hz, 1H), 7.40 (d, J = 8.6 Hz, 1H), 7.19 (d, J = 8.7 Hz, 1H), 6.96 (d, J = 






White solid, 81% yield. 1H-NMR (300 MHz, CDCl3) δ 9.89 (s, 1H), 7.84 (d, 
J = 8.8 Hz, 2H), 7.43 (d, J = 8.8 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.13-7.04 (m, 
4H), 5.10 (s, 2H)146. MS ESI m/z: 231 [M+H]+. 
4-((4-(trifluoromethyl)benzyl)oxy)benzaldehyde 43 
 
White solid, 88% yield. 1H-NMR (300 MHz, CDCl3) δ 9.90 (s, 1H), 7.86 (dd, 
J = 7.0 e 1.8 Hz, 2H), 7.67 (d, J = 8.8 Hz, 2H), 7.55 (d, J = 8.0 Hz, 2H), 7.07 (dd, J 
= 6.6 e 1.8 Hz, 2H), 5.21 (s, 2H)146. MS ESI m/z: 281 [M+H]+. 
4-((3,4-dichlorobenzyl)oxy)benzaldehyde 44 
 
White solid, 77% yield. 1H-NMR (300 MHz, DMSO-d6) δ 9.88 (s, 1H), 7.88 
(d, J = 8.4 Hz, 2H), 7.76 (s, 1H), 7.68 (d, J = 8.3 Hz, 2H), 7.49 – 7.44 (m, 1H), 7.21 






White solid, 75% yield. 1H-NMR (300 MHz, CDCl3) δ 9.89 (s, 1H), 7.85 (d, 
2H, J = 8.6 Hz)7.42e7.48 (m, 2H),7.26e7.30 (m, 1H), 7.07 (d, 2H, J = 8.6 Hz), 5.19 
(s, 2H)148. MS ESI m/z: 282 [M+H]+.  
4-((4-chloro-2-fluorobenzyl)oxy)benzaldehyde 46 
 
White solid, 84% yield. 1H-NMR (300 MHz, DMSO-d6) δ 9.89 (d, J = 1.1 
Hz, 1H), 7.92 – 7.85 (m, 2H), 7.62 (t, J = 8.1 Hz, 1H), 7.55 – 7.49 (m, 1H), 7.39 – 
7.33 (m, 1H), 7.26 – 7.21 (m, 2H), 5.26 (s, 2H). MS ESI m/z: 265 [M+H]+. 
4-((2-chloro-6-fluorobenzyl)oxy)benzaldehyde 47 
 
White solid, 75% yield. 1H-NMR (300 MHz, DMSO-d6) δ 9.90 (s, 1H), 7.90 
(d, J = 8.8 Hz, 2H), 7.59 – 7.30 (m, 3H), 7.26 (d, J = 8.4 Hz, 2H), 5.28 (d, J = 1.9 
Hz, 2H); MS ESI m/z: 265 [M+H]+. 
2-(benzyloxy)benzaldehyde 48 
 
White solid, 79% yield. 1H-NMR (300 MHz, CDCl3) δ 10.55 (s, 1 H,), 7.86–






White solid, 83% yield. 1H-NMR (300 MHz, CDCl3) δ 9.98 (s, 1H), 7.34–
7.49 (m, 8H), 7.23–7.32 (m, 1H), 5.13 (s, 2H)150. MS ESI m/z: 213 [M+H]+. 
Synthesis of 4-formylphenyl 4-methylbenzenesulfonate 50 
 
A suspension of 4-hydroxybenzaldehyde (0.50 g, 4.10 mmol) in dry DCM 
(25.0 mL) was prepared and cooled to 0 °C, then triethylamine (1.1 mL, 8.20 mmol) 
and tosyl chloride (77; 0.86 g, 4.51 mmol) were added respectively. The mixture 
was allowed to slowly warm to room temperature while stirring for 1 h, then was 
washed with water (3 x 10 mL) and brine (10 mL). The organic layer was dried 
over anhydrous sodium sulfate and evaporated. The crude was purified by silica gel 
chromatography (Hexane/EtOAc) to give the title compounds as white solid in 96% 
yield.  
1H-NMR (300 MHz, DMSO-d6) δ 9.97 (s, 1H), 7.98 – 7.88 (m, 2H), 7.77 (d, 
J = 8.4 Hz, 2H), 7.48 (d, J = 8.0 Hz, 2H), 7.30 – 7.24 (m, 2H), 2.42 (s, 3H)151. MS 
ESI m/z: 277 [M+H]+. 
General procedure for the synthesis of 3-hydroxy-2,3-
dihydroquinazolin-4(1H)-one derivatives 
To a solution of 2-amino-N-hydroxybenzamide (33; 0.10 g, 0.66 mmol) in 
methanol (5.0 mL) was added the proper aldehyde. The mixture was stirred at room 
temperature for 1-24 h, then the solvent was removed in vacuo. The crude was 
readily purified by silica gel chromatography (DCM/MeOH) to give the title 







Yield: 84%. 1H NMR (400 MHz, DMSO-d6) δ 9.94 (s, 1H), 9.11 (s, 1H), 8.18 
– 8.10 (m, 1H), 8.09 – 7.99 (m, 1H), 7.93 – 7.85 (m, 2H), 7.74 (dd, J = 7.8, 1.6 Hz, 
1H), 7.66 (d, J = 2.1 Hz, 1H), 7.27 (ddd, J = 8.1, 7.2, 1.6 Hz, 1H), 6.77 (ddd, J = 
8.0, 7.2, 1.0 Hz, 1H), 6.70 (dd, J = 8.2, 1.0 Hz, 1H), 6.21 (d, J = 2.1 Hz, 1H). 13C 
NMR (101 MHz, DMSO) δ 163.22, 153.12, 145.67, 144.42, 141.87, 140.46, 
133.51, 130.69, 130.56, 128.99, 128.89, 127.19, 117.85, 114.26, 113.98, 75.11. MS 
ESI m/z: 293 [M+H]+. 
3-hydroxy-2-(quinolin-2-yl)-2,3-dihydroquinazolin-4(1H)-one 2 (EML621) 
 
Yield: 87%. 1H NMR (400 MHz, DMSO-d6) δ 9.84 (s, 1H), 8.41 (d, J = 8.5 
Hz, 1H), 7.99 (ddd, J = 8.0, 2.0, 1.1 Hz, 2H), 7.78 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 
7.71 (dd, J = 7.8, 1.6 Hz, 1H), 7.69 – 7.54 (m, 3H), 7.23 (ddd, J = 7.8, 7.2, 1.6 Hz, 
1H), 6.72 (td, J = 7.5, 1.0 Hz, 1H), 6.68 (dd, J = 8.2, 1.0 Hz, 1H), 6.06 (d, J = 2.1 
Hz, 1H). 13C NMR (101 MHz, DMSO) δ 162.76, 158.79, 146.50, 145.79, 137.22, 
133.36, 129.87, 128.76, 127.87, 127.72, 127.09, 126.87, 118.81, 117.40, 114.05, 
113.72, 76.77. MS ESI m/z: 292 [M+H]+. 
3-hydroxy-2-(quinolin-3-yl)-2,3-dihydroquinazolin-4(1H)-one 3 (EML622) 
 
Yield: 85%. 1H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 9.02 (d, J = 2.3 




1.5 Hz, 1H), 7.74 – 7.68 (m, 1H), 7.64 (ddd, J = 8.1, 6.9, 1.3 Hz, 1H), 7.57 (d, J = 
1.8 Hz, 1H), 7.30 (ddd, J = 8.0, 7.3, 1.6 Hz, 1H), 6.85 – 6.66 (m, 2H), 6.21 (d, J = 
1.7 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 163.32, 149.97, 147.61, 146.19, 
134.39, 133.58, 132.30, 129.92, 128.66, 128.24, 127.32, 127.02, 126.98, 117.78, 




Yield: 90%. 1H NMR (400 MHz, DMSO-d6) δ 9.75 (s, 1H), 8.01 – 7.78 (m, 
4H), 7.69 (dd, J = 8.0, 1.6 Hz, 1H), 7.63 (dd, J = 8.6, 1.7 Hz, 1H), 7.59 – 7.51 (m, 
2H), 7.49 (d, J = 1.8 Hz, 1H), 7.26 (ddd, J = 8.2, 7.2, 1.6 Hz, 1H), 6.81 – 6.61 (m, 
2H), 6.09 (d, J = 1.8 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 162.80, 146.19, 
137.22, 133.36, 133.03, 132.38, 127.98, 127.91, 127.52, 127.18, 126.37, 126.27, 




Yield: 77%. 1H NMR (400 MHz, DMSO-d6) δ 9.65 (s, 1H), 7.64 (dd, J = 8.1, 
1.6 Hz, 1H), 7.46 – 7.29 (m, 8H), 7.27 – 7.14 (m, 1H), 7.01 – 6.91 (m, 2H), 6.75 – 
6.62 (m, 2H), 5.84 (d, J = 1.8 Hz, 1H), 5.10 (s, 2H). 13C NMR (101 MHz, DMSO) 
δ 162.68, 158.50, 146.21, 136.99, 133.23, 132.13, 128.40, 128.26, 127.78, 127.57, 





4(1H)-one 6 (EML647) 
 
Yield: 81%. 1H NMR (400 MHz, DMSO-d6) δ 9.65 (s, 1H), 7.64 (dd, J = 8.0, 
1.6 Hz, 1H), 7.48 – 7.42 (m, 4H), 7.41 – 7.29 (m, 3H), 7.24 (ddd, J = 8.2, 7.2, 1.6 
Hz, 1H), 7.10 – 6.92 (m, 2H), 6.85 – 6.64 (m, 2H), 5.84 (d, J = 1.8 Hz, 1H), 5.10 
(s, 2H). 13C NMR (101 MHz, DMSO) δ 162.69, 158.29, 146.20, 136.06, 133.25, 
132.33, 132.27, 129.38, 128.40, 128.28, 127.10, 117.20, 114.43, 114.05, 113.70, 
74.45, 68.31. MS ESI m/z: 381 [M+H]+. 
3-hydroxy-2-(4-((4-nitrobenzyl)oxy)phenyl)-2,3-dihydroquinazolin-4(1H)-
one 7 (EML648) 
 
Yield: 83%. 1H NMR (400 MHz, DMSO-d6) δ 9.67 (s, 1H), 8.25 (d, J = 8.4 
Hz, 2H), 7.70 (d, J = 8.3 Hz, 2H), 7.64 (dd, J = 8.0, 1.5 Hz, 1H), 7.39 – 7.30 (m, 
3H), 7.29 – 7.13 (m, 1H), 7.10 – 6.95 (m, 2H), 6.80 – 6.59 (m, 2H), 5.85 (d, J = 1.7 
Hz, 1H), 5.28 (s, 2H). 13C NMR (101 MHz, DMSO) δ 162.68, 158.05, 146.98, 
146.18, 144.98, 133.26, 132.56, 128.34, 128.13, 127.10, 123.59, 117.22, 114.47, 
114.05, 113.70, 74.41, 68.00. MS ESI m/z: 392 [M+H]+. 
3-hydroxy-2-(4-((4-methoxybenzyl)oxy)phenyl)-2,3-dihydroquinazolin-





Yield: 79%. 1H NMR (400 MHz, DMSO-d6) δ 9.64 (s, 1H), 7.64 (dd, J = 8.0, 
1.6 Hz, 1H), 7.41 – 7.30 (m, 5H), 7.24 (ddd, J = 8.1, 7.2, 1.6 Hz, 1H), 7.03 – 6.86 
(m, 4H), 6.78 – 6.64 (m, 2H), 5.84 (d, J = 1.8 Hz, 1H), 5.00 (s, 2H), 3.75 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 162.69, 158.94, 158.56, 146.21, 133.24, 131.99, 
129.37, 128.83, 128.21, 127.10, 117.19, 114.41, 114.04, 113.79, 113.71, 74.48, 
68.94, 55.07. MS ESI m/z: 377 [M+H]+. 
2-(4-((4-fluorobenzyl)oxy)phenyl)-3-hydroxy-2,3-dihydroquinazolin-4(1H)-
one 9 (EML658) 
 
Yield: 80%. 1H NMR (400 MHz, DMSO-d6) δ 9.65 (s, 1H), 7.65 (dd, J = 8.1, 
1.6 Hz, 1H), 7.56 – 7.42 (m, 2H), 7.35 (dd, J = 8.9, 2.3 Hz, 3H), 7.30 – 7.15 (m, 
3H), 7.04 – 6.92 (m, 2H), 6.75 – 6.63 (m, 2H), 5.85 (d, J = 1.8 Hz, 1H), 5.08 (s, 
2H). 13C NMR (101 MHz, DMSO) δ 162.92, 162.70, 160.50, 158.40, 146.21, 
133.26, 133.20, 132.20, 129.88, 129.80, 128.27, 127.11, 117.22, 115.33, 115.12, 
114.42, 114.06, 113.71, 74.46, 68.46. MS ESI m/z: 365 [M+H]+. 
3-hydroxy-2-(4-((4-(trifluoromethyl)benzyl)oxy)phenyl)-2,3-





Yield: 85%. 1H NMR (400 MHz, DMSO-d6) δ 9.65 (s, 1H), 7.78 – 7.71 (m, 
2H), 7.65 (dt, J = 8.0, 1.5 Hz, 3H), 7.40 – 7.29 (m, 3H), 7.24 (ddd, J = 8.2, 7.2, 1.7 
Hz, 1H), 7.05 – 6.91 (m, 2H), 6.75 – 6.58 (m, 2H), 5.85 (d, J = 1.8 Hz, 1H), 5.22 
(s, 2H). 13C NMR (101 MHz, DMSO) δ 162.70, 158.20, 146.20, 141.94, 133.26, 
132.41, 128.34, 127.88, 127.11, 125.33, 125.29, 117.22, 114.44, 114.05, 113.70, 
74.44, 68.27. MS ESI m/z: 415 [M+H]+. 
2-(4-((3,4-dichlorobenzyl)oxy)phenyl)-3-hydroxy-2,3-dihydroquinazolin-
4(1H)-one 11 (EML679) 
 
Yield: 81%. 1H NMR (400 MHz, DMSO-d6) δ 9.65 (s, 1H), 7.70 (d, J = 2.0 
Hz, 1H), 7.65 (dd, J = 8.1, 3.1 Hz, 2H), 7.43 (dd, J = 8.3, 2.0 Hz, 1H), 7.39 – 7.30 
(m, 3H), 7.30 – 7.15 (m, 1H), 7.06 – 6.90 (m, 2H), 6.80 – 6.60 (m, 2H), 5.85 (d, J 
= 1.8 Hz, 1H), 5.12 (s, 2H). 13C NMR (101 MHz, DMSO) δ 162.70, 158.10, 146.19, 
138.29, 133.25, 132.44, 131.06, 130.67, 130.29, 129.36, 128.32, 127.70, 127.10, 
117.22, 114.44, 114.05, 113.70, 74.43, 67.60. MS ESI m/z: 415 [M+H]+. 
2-(4-((2,4-dichlorobenzyl)oxy)phenyl)-3-hydroxy-2,3-dihydroquinazolin-





Yield: 82%. 1H NMR (400 MHz, DMSO-d6) δ 9.70 (s, 1H), 7.69 (d, J = 2.1 
Hz, 1H), 7.66 (dd, J = 8.1, 1.6 Hz, 1H), 7.61 (d, J = 8.3 Hz, 1H), 7.48 (dd, J = 8.3, 
2.1 Hz, 1H), 7.43 – 7.32 (m, 3H), 7.30 – 7.17 (m, 1H), 7.10 – 6.89 (m, 2H), 6.81 – 
6.60 (m, 2H), 5.87 (d, J = 1.7 Hz, 1H), 5.14 (s, 2H). 13C NMR (101 MHz, DMSO) 
δ 162.70, 158.17, 146.19, 133.56, 133.49, 133.44, 133.26, 132.58, 131.30, 128.90, 
128.36, 127.51, 127.10, 117.21, 114.36, 114.05, 113.69, 74.43, 66.32. MS ESI m/z: 
415 [M+H]+. 
2-(4-((4-chloro-2-fluorobenzyl)oxy)phenyl)-3-hydroxy-2,3-
dihydroquinazolin-4(1H)-one 13 (EML681) 
 
Yield: 85%. 1H NMR (400 MHz, DMSO-d6) δ 9.66 (s, 1H), 7.65 (dd, J = 8.1, 
1.6 Hz, 1H), 7.57 (t, J = 8.2 Hz, 1H), 7.49 (dd, J = 10.0, 2.1 Hz, 1H), 7.41 – 7.29 
(m, 4H), 7.24 (ddd, J = 8.1, 7.3, 1.6 Hz, 1H), 7.07 – 6.93 (m, 2H), 6.70 (ddd, J = 
8.1, 5.8, 1.2 Hz, 2H), 5.86 (d, J = 1.8 Hz, 1H), 5.12 (s, 2H). 13C NMR (101 MHz, 
DMSO) δ 162.68, 161.44, 158.95, 158.17, 146.19, 133.78, 133.68, 133.25, 132.51, 
131.76, 131.71, 128.32, 127.10, 124.79, 124.75, 123.13, 122.98, 117.21, 116.22, 
115.97, 114.35, 114.05, 113.70, 74.42, 63.06, 63.02. MS ESI m/z: 399 [M+H]+. 
 2-(4-((2-chloro-6-fluorobenzyl)oxy)phenyl)-3-hydroxy-2,3-





Yield: 80%. 1H NMR (400 MHz, DMSO-d6) δ 9.66 (s, 1H), 7.65 (dd, J = 8.1, 
1.6 Hz, 1H), 7.51 (td, J = 8.2, 6.2 Hz, 1H), 7.46 – 7.30 (m, 5H), 7.28 – 7.17 (m, 
1H), 7.18 – 6.92 (m, 2H), 6.85 – 6.63 (m, 2H), 5.87 (d, J = 1.8 Hz, 1H), 5.14 (d, J 
= 1.9 Hz, 2H). 13C NMR (101 MHz, DMSO) δ 162.73, 162.59, 160.11, 158.48, 
146.21, 135.44, 135.38, 133.27, 132.58, 131.83, 131.73, 128.35, 127.11, 125.71, 
121.99, 121.81, 117.22, 114.87, 114.65, 114.21, 114.05, 113.70, 74.46, 60.90, 




Yield: 74%. 1H NMR (400 MHz, DMSO-d6) δ 9.80 (s, 1H), 7.65 (dd, J = 8.0, 
1.6 Hz, 1H), 7.51 – 7.18 (m, 8H), 7.09 (dd, J = 2.5, 1.7 Hz, 1H), 7.05 – 6.88 (m, 
2H), 6.80 – 6.50 (m, 2H), 5.88 (d, J = 2.0 Hz, 1H), 5.06 (s, 2H). 13C NMR (101 
MHz, DMSO) δ 162.48, 158.23, 146.02, 141.60, 136.86, 133.27, 129.32, 128.40, 
127.83, 127.72, 127.09, 119.28, 117.28, 114.38, 114.09, 113.76, 113.66, 74.58, 







Yield: 77%. 1H NMR (400 MHz, DMSO-d6) δ 9.76 (s, 1H), 7.67 (dd, J = 7.7, 
1.6 Hz, 1H), 7.51 (ddt, J = 7.5, 1.4, 0.7 Hz, 2H), 7.44 – 7.36 (m, 2H), 7.36 – 7.29 
(m, 1H), 7.29 – 7.24 (m, 2H), 7.22 (ddd, J = 8.2, 7.2, 1.7 Hz, 1H), 7.11 (dd, J = 8.4, 
1.0 Hz, 1H), 7.05 (d, J = 2.3 Hz, 1H), 6.91 (td, J = 7.5, 1.0 Hz, 1H), 6.77 – 6.65 (m, 
2H), 6.31 (d, J = 2.0 Hz, 1H), 5.20 (s, 2H). 13C NMR (101 MHz, DMSO) δ 162.63, 
155.68, 145.88, 137.08, 133.14, 129.62, 128.41, 127.70, 127.64, 127.29, 126.99, 
126.76, 120.34, 117.17, 114.24, 113.61, 112.69, 69.48, 69.31. MS ESI m/z: 347 
[M+H]+. 
4-(3-hydroxy-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)phenyl 4-
methylbenzenesulfonate 17 (EML651) 
 
Yield: 65%. 1H NMR (400 MHz, DMSO-d6) δ 9.75 (s, 1H), 7.75 (d, J = 8.1 
Hz, 2H), 7.64 (dd, J = 7.7, 1.4 Hz, 1H), 7.56 – 7.36 (m, 5H), 7.25 (td, J = 7.6, 1.5 
Hz, 1H), 7.05 (d, J = 8.6 Hz, 2H), 6.86 – 6.63 (m, 2H), 5.91 (d, J = 1.8 Hz, 1H), 
2.42 (s, 3H). 13C NMR (101 MHz, DMSO) δ 162.66, 149.00, 145.99, 145.78, 
139.01, 133.43, 131.59, 130.25, 128.73, 128.09, 127.16, 121.85, 117.46, 114.10, 
113.55, 74.13, 21.16. MS ESI m/z: 411 [M+H]+. 





Yield: 82%. 1H NMR (400 MHz, DMSO-d6) δ 9.77 (s, 1H), 7.65 (dd, J = 7.8, 
1.5 Hz, 1H), 7.49 – 7.38 (m, 2H), 7.33 (t, J = 7.3 Hz, 2H), 7.30 – 7.21 (m, 3H), 6.76 
(d, J = 8.1 Hz, 1H), 6.74 – 6.63 (m, 2H), 6.39 (dd, J = 15.8, 7.0 Hz, 1H), 5.43 (dd, 
J = 7.0, 1.9 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 162.31, 146.10, 135.56, 
133.25, 132.84, 128.69, 128.17, 127.18, 126.65, 125.92, 117.34, 114.35, 113.78, 




Yield: 88%. 1H NMR (400 MHz, DMSO-d6) δ 9.80 (s, 1H), 7.77 – 7.61 (m, 
5H), 7.56 – 7.49 (m, 2H), 7.49 – 7.41 (m, 3H), 7.41 – 7.30 (m, 1H), 7.26 (ddd, J = 
8.2, 7.2, 1.6 Hz, 1H), 6.82 – 6.57 (m, 2H), 5.96 (d, J = 2.0 Hz, 1H). 13C NMR (101 
MHz, DMSO) δ 162.64, 146.11, 140.46, 139.71, 139.06, 133.34, 128.91, 127.52, 
127.15, 126.68, 126.56, 117.32, 114.11, 113.75, 74.53. MS ESI m/z: 317 [M+H]+. 
3-hydroxy-2-phenyl-2,3-dihydroquinazolin-4(1H)-one 20 (EML659) 
 
Yield: 68%. 1H NMR (400 MHz, DMSO-d6) δ 9.74 (s, 1H), 7.66 (dd, J = 8.0, 
1.6 Hz, 1H), 7.50 – 7.39 (m, 3H), 7.39 – 7.29 (m, 3H), 7.29 – 7.19 (m, 1H), 6.78 – 
6.61 (m, 2H), 5.90 (d, J = 1.9 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 162.65, 
146.13, 139.91, 133.32, 128.53, 128.21, 127.12, 126.94, 117.29, 114.07, 113.71, 







Yield: 71%. 1H NMR (400 MHz, DMSO-d6) δ 9.79 (s, 1H), 7.66 (dd, J = 8.0, 
1.6 Hz, 1H), 7.50 – 7.40 (m, 5H), 7.26 (ddd, J = 8.1, 7.2, 1.6 Hz, 1H), 6.80 – 6.60 
(m, 2H), 5.93 (d, J = 2.0 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 162.68, 145.98, 
138.84, 133.41, 133.10, 128.88, 128.21, 127.16, 117.46, 114.13, 113.67, 74.11, 




Yield: 73%. 1H NMR (400 MHz, DMSO-d6) δ 9.98 (s, 1H), 8.36 – 8.20 (m, 
2H), 7.79 – 7.63 (m, 3H), 7.59 (s, 1H), 7.36 – 7.22 (m, 1H), 6.74 (t, J = 7.5 Hz, 2H), 
6.11 (d, J = 2.3 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 162.58, 147.60, 147.11, 
145.73, 133.55, 128.31, 127.22, 123.49, 117.73, 114.26, 113.68, 73.80. MS ESI 




Yield: 70%. 1H NMR (400 MHz, DMSO-d6) δ 9.64 (s, 1H), 7.65 (dd, J = 8.2, 
1.6 Hz, 1H), 7.41 – 7.30 (m, 3H), 7.30 – 7.12 (m, 1H), 7.01 – 6.81 (m, 2H), 6.82 – 




δ 162.71, 159.45, 146.23, 133.24, 131.89, 128.25, 127.10, 117.19, 114.05, 113.71, 




Yield: 67%. 1H NMR (400 MHz, DMSO-d6) δ 9.47 (s, 2H), 7.64 (dd, J = 8.1, 
1.7 Hz, 1H), 7.43 – 6.91 (m, 4H), 6.80 – 6.36 (m, 4H), 5.78 (s, 1H). 13C NMR (101 
MHz, DMSO) δ 162.70, 157.68, 146.32, 133.21, 130.18, 128.30, 127.09, 117.09, 
114.80, 113.98, 113.63, 74.75. MS ESI m/z: 257 [M+H]+. 
3-hydroxy-2-(p-tolyl)-2,3-dihydroquinazolin-4(1H)-one 25 (EML656)  
 
Yield: 71%. 1H NMR (400 MHz, DMSO-d6) δ 9.72 (s, 1H), 7.64 (dd, J = 8.1, 
1.6 Hz, 1H), 7.38 (d, J = 2.1 Hz, 1H), 7.34 – 7.28 (m, 2H), 7.26 – 7.19 (m, 1H), 
7.16 (d, J = 7.9 Hz, 2H), 6.83 – 6.59 (m, 2H), 5.86 (d, J = 1.9 Hz, 1H), 2.28 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 162.53, 146.10, 137.77, 137.02, 133.19, 128.67, 







Yield: 75%. 1H NMR (400 MHz, DMSO-d6) δ 9.88 (s, 1H), 7.81 – 7.72 (m, 
2H), 7.73 – 7.59 (m, 3H), 7.51 (d, J = 2.1 Hz, 1H), 7.34 – 7.19 (m, 1H), 6.73 (td, J 
= 7.5, 1.1 Hz, 2H), 6.04 (d, J = 2.0 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 162.69, 
145.88, 144.39, 133.48, 129.23, 128.91, 128.70, 127.85, 127.19, 125.23, 125.20, 




Yield: 73%. 1H NMR (400 MHz, DMSO-d6) δ 9.90 (s, 1H), 7.72 – 7.61 (m, 
3H), 7.49 (d, J = 2.2 Hz, 1H), 7.45 – 7.37 (m, 1H), 7.33 – 7.21 (m, 1H), 6.85 – 6.49 
(m, 2H), 5.98 (d, J = 2.1 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 162.70, 145.79, 
140.91, 133.54, 131.08, 130.86, 130.54, 129.15, 127.21, 127.20, 117.71, 114.23, 




Yield: 77%. 1H NMR (400 MHz, DMSO-d6) δ 9.81 (s, 1H), 7.73 – 7.61 (m, 
2H), 7.57 – 7.43 (m, 2H), 7.39 (d, J = 2.1 Hz, 1H), 7.27 (ddd, J = 8.1, 7.2, 1.6 Hz, 
1H), 6.80 – 6.63 (m, 2H), 6.29 (d, J = 2.0 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 
162.92, 145.58, 135.65, 133.95, 133.58, 133.30, 129.73, 129.03, 127.62, 127.19, 







Yield: 74%. 1H NMR (400 MHz, DMSO-d6) δ 9.84 (s, 1H), 7.68 (dd, J = 7.8, 
1.6 Hz, 1H), 7.55 – 7.38 (m, 3H), 7.32 (ddd, J = 8.4, 2.0, 0.8 Hz, 1H), 7.30 – 7.22 
(m, 1H), 6.88 – 6.57 (m, 2H), 6.19 (d, J = 2.0 Hz, 1H). 13C NMR (101 MHz, DMSO) 
δ 162.75, 161.27, 158.77, 145.79, 134.12, 134.01, 133.50, 129.71, 129.69, 129.67, 
127.15, 125.93, 125.80, 124.71, 124.70, 124.68, 117.56, 116.38, 116.13, 114.09, 




Yield: 73%. 1H NMR (400 MHz, DMSO-d6) δ 9.82 (s, 1H), 7.65 (dd, J = 7.8, 
1.5 Hz, 1H), 7.50 – 7.38 (m, 2H), 7.36 (dt, J = 8.1, 1.0 Hz, 1H), 7.30 – 7.13 (m, 
2H), 6.73 – 6.64 (m, 2H), 6.60 (dd, J = 8.2, 1.0 Hz, 1H). 13C NMR (101 MHz, 
DMSO) δ 163.20, 161.16, 160.69, 145.77, 133.96, 133.90, 133.15, 131.18, 131.09, 
126.86, 125.96, 125.93, 124.58, 124.43, 116.74, 115.63, 115.40, 113.23, 112.79, 
69.79. MS ESI m/z: 293 [M+H]+. 
General procedure for the synthesis of quinazolin-4(3H)-ones (31-32) 
To a suspension of proper 3-hydroxy-2,3-dihydroquinazolin-4(1H)-one (1-2; 
0.50 mmol) in toluene (10.0 mL) was added selenium dioxide (0.11 g, 1,00 mmol), 
then the mixture was refluxed for 4 hours. The hot mixture was filtered through 
Celite and the crude was purified by silica gel chromatography (Hex/EtOAc) to give 
the title compounds in 80% yield as light brown solid. 





Yield: 80%. 1H NMR (400 MHz, CDCl3) δ 10.86 (s, 1H), 10.05 (s, 1H), 8.40 
(d, J = 7.9 Hz, 0H), 8.27 – 8.21 (m, 1H), 8.21 – 8.13 (m, 1H), 7.98 – 7.80 (m, 4H), 
7.66 – 7.53 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 161.32, 148.92, 147.76, 
143.86, 143.78, 142.66, 140.67, 135.03, 131.93, 131.34, 129.73, 128.70, 128.34, 
127.03, 122.95, 120.14. MS ESI m/z: 275 [M+H]+. 
2-(quinolin-2-yl)quinazolin-4(3H)-one 32 (EML626) 
 
Yield: 80%. 1H NMR (400 MHz, CDCl3) δ 11.19 (s, 1H), 8.61 (d, J = 8 Hz, 
1H), 8.34 (t, J = 8 Hz, 2H), 8.12 (d, J = 8 Hz, 1H), 7.65-7.90 (m, 4H), 7.45-7.65 (m, 
2H)152. 13C NMR (101 MHz, CDCl3) δ 161.3, 149.1, 148.9, 148.0, 146.7, 137.5, 
134.4, 130.4, 129.6, 129.2, 128.2, 127.6, 127.4, 126.7, 122.6, 118.4152. MS ESI m/z: 
274 [M+H]+. 
 
6.7 Histone processing and mass spectrometry analysis 
Histone bands were separated by SDS-PAGE, stained with Coomassie 
(Brillant blue G-250) and excised at appropriate height. Bands were destained in 
50% acetonitrile/50% 100 mM ammonium bicarbonate. Histones were chemically 
modified by propionylation (30 min, room temperature, 2.5% propionic anhydride 
(Sigma) in ammonium bicarbonate at pH 7.5) to prevent tryptic cleavage. Histone 
proteins were then digested with trypsin (Promega, 200 ng in 50 mM ammonium 
bicarbonate) overnight and the supernatant desalted by Carbon TopTips (Glygen) 
according to manufacturer’s instructions. The peptides were injected in an Ultimate 




to 60% acetonitrile in 0.1% formic acid over 40 min at 300 nl/min on a 75 μm ID 
X 10 cm ReproSil-Pur C1-AQ analytical column (2.4 μm; Dr. Maisch GmbH 
Germany). The effluent from the HPLC was directly electro-sprayed into the Q 
Exactive™ HF hybrid quadrupole-Orbitrap mass spectrometer (Thermo Fisher 
Scientific). The MS instrument was operated in the data-dependent mode to 
automatically switch between full scan MS and MS/MS acquisition. Survey full 
scan spectra (m/z 250–2000) were acquired in the Quadrupole-Orbitrap with 
resolution R = 60 000 at m/z 400. For all measurements with the Quadrupole-
Orbitrap detector, three lock-mass ions from ambient air (m/z = 371.10123, 
445.12002, 519.13882) were used for internal calibration. The six most intense 
peptide ions with charge state between two and five were sequentially isolated 
(window = 2.0 m/z) to a target value of 10 000 and fragmented in the linear ion trap 
by collision-induced dissociation (CID). Fragment ion spectra were recorded in the 
linear trap of the instrument. A dynamic exclusion time of 180 s was applied. 
Typical mass spectrometric conditions were: spray voltage 1.4 kV; no sheath and 
auxiliary gas flow; heated capillary temperature 200 °C; normalized collision 
energy 35% for CID in linear ion trap. An activation q = 0.25 and activation time 
of 30 ms were used. Data analysis was performed Skyline software (MacCoss Lab 
Software) by using doubly and triply charged peptide masses for extracted ion 
chromatograms (XICs). XICs were checked manually and values exported to Excel 
for further calculations.  
 
6.8.  AlphaLISA KDM4 assay  
The assays were performed in white Optiplate-384 (PerkinElmer, # 6007299) 
at room temperature in a final volume of 20 μL, using the following Assay Buffer: 
50 mM Hepes pH 7.5, 0.01% Tween-20, 0.1% BSA. hKDM4A (BPS BioScience # 
50103) (100 nM, final concentration) was diluted in Assay Buffer, then a mixture 
of Fe(II) (Sigma # 215406) (5 μM, final concentration), ascorbate (Sigma # 11140) 
(100 μM, final concentration) and proper inhibitor (5% DMSO, final concentration) 
was added. After a pre-incubation time of 15 minutes, Histone H3 (1 - 21) lysine 9 




concentration) and 2OG (Sigma # K2000) (5 μM, final concentration) were added. 
The reaction was incubated for 1 h, afterwards the Anti-methyl-Histone H3 Lysine 
9 (H3K9me2) AlphaLISA Acceptor beads (PerkinElmer # AL117 PerkinElmer # 
AL117) in Epigenetic Buffer 1X was added in each well, to reach a final 
concentration of 20 μg/mL. After an incubation of 1 h, Streptavidin Donor beads 
(PerkinElmer, # 6760002) were diluted in Epigenetic Buffer 1X and added in each 
well to reach a final concentration of 20 μg/mL. After 30 minutes of incubation, the 
Alpha signal was read with the EnSpire Multilabel plate Reader (PerkinElmer). All 
incubation steps with AlphaScreen beads were performed at room under subdued 
lighting condition. 
 
6.9. Hit validation stability assays 
Hit compounds EML586, EML620 and EML627 were dissolved in PBS to 
reach a final concentration of 100 μM (5% DMSO). 5 μL of the prepared solutions 
were analysed by HPLC after 5, 15, 30, 60 minutes and 24 h. Spectra were recorded 
on a Shimadzu SPD 20A UV/vis detector (λ = 220 nm) using C-18 column 
Phenomenex Synergi Fusion RP 80A (75mm × 4.60 mm; 4 μm) at 25 °C using a 
mobile phase A (water + 0.1% TFA) and B (MeCN + 0.1% TFA) at a flow rate of 
1 mL/min. 














Figure 4.3. HPLC chromatograms obtained for compound EML586 (up) and 
EML615 (down) injected immediately after the dissolution in PBS, after 5, 15, 
30, 60 minutes and 24 h. Spectra were recorded at 220 nm. 
 
6.10. PAMPA 
Donor solution (0.5 mM) was prepared by diluting 1 mM dimethyl sulfoxide 
(DMSO) compound stock solution using phosphate buffer (pH 7.4, 0.01 M). Filters 
were coated with 5 μL of a 1% (w/v) dodecane solution of phosphatidylcholine. 
Donor solution (150 μL) was added to each well of the filter plate. To each well of 
the acceptor plate were added 300 μL of solution (50% DMSO in phosphate buffer). 
Compounds were tested in triplicate. The sandwich was incubated for 24 h at room 
temperature under gentle shaking. After the incubation time, the sandwich plates 
were separated and 250 μL of the acceptor plate were transferred to a UV quartz 
microtiter plate and measured by UV spectroscopy, using a Multiskan GO 
microplate spectrophotometer (Thermo Scientific) at 250-500 nm at step of 5 nm. 
Reference solutions (250 μL) were prepared diluting the sample stock solutions to 
the same concentration as that with no membrane barrier. The apparent 
permeability value Papp is determined from the ratio r of the absorbance of 
compound found in the acceptor chamber divided by the theoretical equilibrium 
absorbance (determined independently) applying the Faller modification of Sugano 
equation:  














(𝑉𝐷 + 𝑉𝑅) ∗ 𝐴𝑡
) ∗ ln⁡(1 − 𝑟) 
In this equation, VR is the volume of the acceptor compartment (0.3 cm3), 
VD is the donor volume (0.15 cm3), A is the accessible filter area (0.24 cm2), and t 
is the incubation time in seconds. 
 
6.11. Nephelometric assay 
Stock solutions of test compound (500 μM in DMSO) were diluted into water 
or AlphaLISA Assay Buffer (50 mM Hepes pH 7.5, 0.01% Tween-20, 0.1% BSA) 
and put in 96 well plates to final concentrations of 25 µM (5% DMSO, 300 µL of 
each). The mixtures were incubated at room temperature and scattering was 
measured immediately after preparation of samples (T0) and after 60 min. Each 
measurement has been preceded by a stirring step (2 min, 600 rpm) to re-suspend 
any precipitated particles. All tests were performed in duplicate for each sample. 
Solubility was measured on a Nepheloskan Ascent plate reader equipped with a 
quartz halogen lamp and photomultiplier detector operating between 580 and 630 
nm with a measurement angle of 90 degrees. The instrument settings were the 
following: PMT voltage 450; lamp voltage 11.0. 
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